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1 Introduction 
1.1 The effects of the glucocorticoid hormone 
1.1.1 Target organs of the glucocorticoid hormone  
The name “glucocorticoid” derives from early observations that these 
hormones were involved in glucose metabolism [1]. Regarding the chemical 
structure of the glucocorticoid hormone (GC) it belongs to the family of the 
steroid hormones [2]. Glucocorticoids are mainly produced in mammalians in 
the cortex of the adrenal glands [2]. There are multiple slightly different steroid 
molecules produced here, which are characterised by the ability to bind the 
glucocorticoid receptor (GR) and trigger similar effects. The most important 
physiologically produced GC is cortisol, which has a great range of effects on 
the various target tissues. Among the GC target organs are the brain [3], 
bones [4], cardiovascular system [5], immune system [6], kidneys [7], skin [8], 
liver [1], adipose tissue [9] and skeletal muscles [10]. The GC exerts its effects 
primarily through the glucocorticoid receptor (GR) but recently new GR-
independent mechanisms of actions have been described.  
1.1.2 The structure of the glucocorticoid receptor (GR) 
The GR belongs to the nuclear receptor superfamily [2]. This terminology 
refers to the fact that the active forms of these receptors reside in the nucleus. 
Ligand-free GR is inactive and located in the cytoplasm. Other hormones with 
steroid structure (e.g. Estrogen, progesterone, testosterone, aldosterone) and 
other, structurally non-steroid but lipophil hormones (eg. Tiroxin and retinoic 
acid) have receptors of similar structure. (Figure 1.) Nevertheless, there are 
data about proteins which are structurally similar to steroid receptors, but their 
ligands are unknown (orphan receptors) [2]. 
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Figure 1. Comparison of the primary structure of the nuclear receptors. Figure reproduced 
after Lodish et al. [11]   
 
The GR is an evolutionary conserved transcription factor. GR with high 
functional and structural homology can be found in fishes [12], amphibians 
[13], rodents, and men. The gene encoding the human GR (hGR) is located 
on the long arm of the 5th chromosome (locus 5q31p) [14]. The gene consists 
of 9 exons, of which the 2-9 exons are encoding the GR protein. 3 promoters 
have been identified before the hGR gene (1A, 1B and 1C). The exact 
regulatory function of these sequences is unknown yet, but presumably they 
play a role in the regulation of tissue-specific GR expression [15]. The 
alternative splicing of hGR mRNA results in the expression of two isoforms: 
hGRα and hGRβ. The α isoform is the “classical” 777 amino acid protein 
expressed almost ubiquitously among tissues. It is found in its inactive form in 
the cytoplasm in a macromolecular complex with other proteins [16]. 
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Figure 2. The primary structure of the GR shown on a ribbon diagram. Figure reproduced 
after Necela and Cidlowsky [6]. 
 
Functionally GR can be divided into 4 different domains. (Figure 2.) The N-
terminal domain is the regulatory domain (amino acid residues 1-421). This 
region is responsible for the constitutive transcription activation function. The 
DNA binding domain (DBD, aa. residues 422-486) is the evolutionary most 
conserved part of the molecule possessing a zinc-finger structure. This part of 
the molecule binds to the specific palindrome DNA sequences called 
glucocorticoid response elements (GRE) thus regulating gene transcription. A 
short hinge region (aa. residues 487-526) connects the ligand binding domain 
(LBD, aa residues 527-777) which is also responsible for the formation of the 
homodimer.  
The hGRβ isoform is formed via the alternative splicing of exon 9. It differs 
only in its C-terminal region from hGRα containing a 15 aa long unique 
sequence. The function of hGRβ is controversial: it does not bind ligand and 
localised exclusively in the nucleus. Some studies demonstrate the role of 
hGRβ in pathological GC resistance cases. It may take part in the fine tuning 
of GR-regulated gene expression [6]. 
 
1.1.3 Genomic signal transduction pathways of the nuclear 
receptors 
The ligands of the nuclear receptors are lipophil molecules so they are able to 
penetrate freely through biological membranes. Most of them are chemically 
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steroids (glucocorticoids, mineralocorticoids, sex-steroides, Vitamin D) but 
there are also some non-steroid lipophilic molecules (retinoic acid, thyroxine 
and Triiodothyronine). [2] These hormones diffuse into the cytoplasm and bind 
to their intracellular receptors. The ligand bound receptors then actively 
translocate into the nucleus and bind specific regulatory DNA sequences. 
They act as transcription factors and regulate (either positively or negatively) 
the expression of certain genes. This way of transcription regulation is DNA-
dependent. There are examples of DNA-independent transcription regulation 
e.g. ligand bound steroid receptor interaction with other transcription factors or 
signalling proteins thus modulating their activity. In case of GR there are 
examples of both DNA dependent and independent regulation mechanisms 
[6]. A common characteristic of the genomic signal transduction pathways are 
that the effects can be abolished by either antibiotics inhibiting transcription 
(eg. Actinomycin-D) [17] or drugs inhibiting protein synthesis (eg. 
Cycloheximide) [17]. The onset of genomic effects is always slow: it usually 
takes at least a few hours till the new protein is expressed and exerts its effect 
[18]. 
 
1.1.4 Molecular mechanisms of the genomic signal transduction 
pathway of the GR. 
The inactive GR is associated with other proteins in the cytoplasm like the 
Hsp-90, Hsp-70, immunophillins like p59 and p23 [16]. Due to the 
comformation changes following ligand binding, the GR dissociates the Hsp-
90 complex and translocates into the nucleus as a homodimer [19]. This 
process is actively supported by the elements of the cytoskeletal network, [20] 
e.g GR is known to be associated with tubulin [21]. The function of ligand-
bound GR in the nucleus is mainly transcription regulation. It binds GRE 
sequences, and enhances the transcription of the genes containing this 
element. The GRE sequence is fairly well characterised: 
GGTACAnnnTGTTCT [22]. The GR may implement negative transcription 
regulation either as it may bind negative regulatory GRE (nGRE) as well. 
Such nGRE sequences were described in the promoters of HIV type 1 [23], 
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human osteocalcin [24] and human corticotrophin releasing hormone (CRH) 
genes [25]. However, these nGRE sequences are less well characterised yet.  
The regulation of transcription by GR can be exerted via other ways: 
“communication” with other transcription factors. During this process, the GR 
establishes close physical contact with the other molecule and changes its 
activity. Many other transcription factors are known to interact with GR like the 
NFκB, AP-1, CREB, STAT-1, STAT-3 and STAT-5 (Figure 3, [6]). 
 
 
Figure 3.  
Basic mechanisms of glucocorticoid receptor (GR) action. Left: The GR resides in the 
cytoplasm complexed with several chaperones including hsp90 and immunophilin p59. On 
binding to glucocorticoids, the activated receptor dissociates from the attached accessory 
proteins and translocates into the nucleus. Middle: The GR then regulates the expression of 
genes by several basic modes of action. From top to bottom: The GR binds as a dimer to 
glucocorticoid response elements (GREs) in target genes to activate gene transcription; the 
GR binds to negative GREs (nGREs) and inhibits target gene transcription; the GR physically 
interacts with the c-Jun subunit of the AP-1 complex to inhibit AP-1-mediated gene 
expression; the GR physically interacts with the p65 (RelA) subunit of NF- B and represses 
NF- B-regulated gene expression; the GR physically interacts with members of the STAT 
family (STAT1, STAT5, and STAT3) and synergistically enhances STAT-regulated gene 
transcription. GTM = general transcriptional machinery; P = phosphate. Right: Examples of 
genes regulated by the GR by the various mechanisms are shown. Figure reproduced after 
Necela and Cidlowsky [6]  
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1.1.5 Non-genomic effects of GC 
Common feature of the non-genomic steroid hormone effects is that no de 
novo protein synthesis is necessary. Non-genomic effects are mainly 
characterised by post-translational modifications of already existing signal 
transduction molecules. These reactions may occur considerably fast, as they 
show within seconds or minutes. The non-genomic GC effects are divided into 
3 groups according to Buttgereit and colleagues: (1) specific GC effects 
accomplished through the classical cytoplasmic GR (cGR). These cytoplasmic 
effects are mainly exerted via GR interactions with other signalling proteins. 
(2) Specific GC effects involving the putative membrane resident GR (mGR) 
and (3) non-specific GC effects via physicochemical membrane interactions. 
(Figure 4.) This latter one can be considered only by very high hormone 
concentration [26]. 
 
 
Figure 4. 
Non-genomic effects of GCs. I.: non-genomic GC action involving cGR. II.: non-genomic GC 
effects accomplished via the putative mGR. III.: non-genomic GC effects exerted by direct 
physicochemical membrane actions.  
 
1.1.6 Specific rapid GC effects directed by the cGR 
Good examples for the rapid, non-genomic effects mediated by the cGR are 
the results described by Croxtall and co-workers: the cytosolic phospholipase 
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A2 (cPLA2) activation and arachidonic acid secretion following EGF stimulation 
can be rapidly inhibited by Dexamethasone (DX) treatment [27]. The process 
proved to be insensitive to actinomycin and sensitive to RU486 which clearly 
suggests non-genomic signalling pathway involving the cGR. The authors 
propose the participation of src-kinase in the signalling pathway. Since the 
src-family kinases are Hsp-90 associated and the inactive GR is localised in 
the same macromolecular compartment, the ligand-binding and the 
consequential dissociation of the ligand-bound GR may initialize mechanisms 
which result in the observed outcome [27]. 
 
1.1.7 Specific GC effects involving the putative mGR 
Membrane resident receptors were described concerning every steroid 
hormone [28]. However, data about mGR are remarkably obscure. The 
presence of classic cGR-like antigen was shown in the membrane of murine 
T-cell leukaemia [29] and on the surface of human leukaemic cells [30]. 
Gametchu and co-workers proposed a relation between the presence of the 
mGR and the sensitivity of the cells to GC-induced cell death [31, 32]. They 
demonstrated that the mGR expression level is cell-cycle dependent [32]. 
Others detected mGR on the surface of human PBMC [33]. We were able to 
show membrane associated GR on the surface of Jurkat cells [34]. Evans et 
al. described the partial purification of a membrane-resident GC binding 
protein from the brain of the rough skin newt (Taricha granulosa), that 
exhibited different structure than that of the classical cGR. The attributes of 
this acidic glycoprotein of 63kDa resembled the 7TM G-protein linked 
receptors [35]. Other steroids also have been shown acting on membrane 
receptors of different structure. A caveola-associated estrogen receptor was 
described by Chambiss and colleagues on the surface of mammary tumor 
cells [36]. A progesterone membrane receptor of 7TM domain structure was 
isolated and cloned from spotted sea trout (Cynoscion nebulosus) eggs [37]. 
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1.1.8 Non-specific GC effects due to physicochemical membrane 
interactions 
Buttgereit and his colleagues take a clinical experience as a base point: 
namely, that daily 100-200 mg orally administered prednisolon equivalent GC 
is able to saturate the specific binding capacity of the GR. In contrast to this 
fact, concerning some particular cases better therapeutic effects were 
achieved by giving a high dose iv. bolus of 500-1000 mg methylprednisolone 
[26]. This observation raised the possibility that in the high-dose range there 
are different GC mechanisms of action. Studying the effects of high dose GC 
effects on mitogen-activated rat thymocytes they observed that 
methylprednisolone inhibited the oxidative phosphorylation (ATP-producing 
processes) and oxygen consumption [38]. GC proved to inhibit the ion-
transport across the plasma membrane in mitogen-activated thymocytes [39]. 
They considered these effects as non-specific membrane effects, showing at 
extremely high GC concentrations. In these in vitro experimental systems the 
administered GC concentrations were 1-10mM. 
 
1.1.9 The regulation of inflammatory response 
Inflammation is the response of the body to tissue damage which can be the 
result of physical trauma, infection, or other pathological conditions. The main 
role of the inflammatory response is the isolation of the harmful agent so that 
it is prevented from spreading throughout the rest of the body, the 
neutralization/elimination of the potential infectious agent and the repair of the 
caused tissue damage. The local inflammation is often accompanied by 
systemic response, called acute phase reaction [40]. The local signs of 
inflammation are redness and heat (due to the blood flow of increased 
volume, but slower speed) and swelling (due to increased vascular 
permeability). In the site of the inflammation the vascular endothelium 
expresses many different adhesion molecules directing the migration and the 
extravasation of the cellular elements participating in the inflammatory 
reaction. [40] In the regulation of the inflammation chemokines, cytokines, and 
other soluble factors are participating. The inflammatory cytokines produced 
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by macrophages are of primary importance in this process. These are TNF-α, 
IL-1, IL-6, CXCL-8 (IL-8), and IL-12 [40]. 
 
 
Table 1.  
Physiological effects of inflammatory cytokines. Table modified after [40] 
 
1.1.10 GR communication with AP-1 and NFκB signal 
transduction pathways 
The transcription factor AP-1 is one of the key molecules of signal 
transduction pathways activated by the inflammatory cytokines (TNFα, IL-1β). 
The AP-1 complex consists of the heterodimer of c-fos and c-jun family 
member proteins. Both have leucin-zipper structure: c-fos family members 
have direct transcription-activating activity, while members of c-jun family 
have only regulatory role. The ligand-bound GR associates with the c-jun 
Inflammatory 
cytokine 
IL-1 TNF-α IL-6 CXCL-8 IL-12 
Local effect Vascular 
endothelium 
activation 
Lymphocyte 
activation 
Tissue 
destruction 
Vascular 
endothelium 
activation 
Increased 
vascular 
permeability: 
migration of 
inflammatory 
cells, IgG and 
complement 
Lymphocyte 
activation 
Increase of 
antibody 
production 
Chemotaxis: 
Enhancing 
the migration 
of 
Neutrophiles, 
Basophiles, 
T-
Lymphocytes 
Activation of 
NK cells 
 
Promoting 
Th1 
differentiation 
Systemic 
effect 
Fever 
Increase of 
IL-6 
production  
Fever 
Mobilisation of 
metabolism 
Fever 
Production 
of Acut 
phase 
proteins  
  
Signal 
transduction 
pathway 
NFκB, AP-1 NFκB, AP-1 JAK - STAT G-protein 
linked 
receptor 
JAK - STAT 
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member of the heterodimer and thereby inhibits the transcription of pro-
inflammatory genes with AP-1 responsive element (eg. collagenase). (Figure 
5. [6]).  
Recent data suggest that the GR inhibits the mitogen-activated protein kinase 
(MAPK) signal transduction pathway as well. The members of the MAPK 
cascade are serine-threonine kinase enzymes, playing important role in the 
signalling originating from cytokine receptors. JNK is a member of the MAPK 
cascade, being responsible for the activation of the AP-1 complex, while the 
p38 subfamily have important function by maintaining the stability of the 
mRNA transcripts of the TNFα, IL-6, CXCL-8, VEGF genes. There are 
multiple data on GR interfering with kinases of the MAPK cascade. GR inhibits 
JNK activity, thus arresting c-jun phosphorylation and preventing AP-1 
activation [41]. GR is known to increase the expression of MAPK-
phosphatase-1, thereby inhibiting the activity of p38 MAPK. Because of the 
increased expression of phosphatases the mRNA transcripts of 
proinflammatory genes become instable [42].  
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Figure 5.  
Mechanisms of cross-talk between the glucocorticoid receptor and the AP-1 complex. 
Cytokines such as IL-1ß and TNF-  bind to and activate membrane-bound cytokine 
receptors. In turn, the cytokine receptor activates c-Jun N-terminal kinase (JNK), a member of 
the MAPK family. JNK phosphorylates the c-Jun subunit of AP-1, which is localized in the 
cytoplasm. Phosphorylation of c-Jun induces its activation and subsequent translocation into 
the nucleus. The c-Jun subunit then dimerizes with the transcriptionally active c-Fos subunit, 
and binds AP-1 response elements to regulate gene expression. The c-Jun subunit of AP-1 
can also physically interact with the GR and repress GR-mediated gene transcription. 
Reciprocally, the GR can physically interact with c-Jun and repress AP-1-mediated gene 
expression. The mechanism by which physical interaction between c-Jun and the GR leads to 
mutual antagonism remains unclear. Alternatively, the GR can repress AP-1 signaling through 
induction of the MAPK phosphatase-1 (MKP-1) gene. MKP-1 prevents phosphorylation of 
JNK and its subsequent activation. Figure reproduced afterNecela and Cidlowsky [6]. 
 
NFκB is an ubiquitously expressed transcription factor playing key role in 
inflammatory reactions. NFκB is a dimeric molecule consisting of a p50 and a 
p65 subunit, the latter being transcriptionally active [43]. Inactive NFκB is 
associated with the inhibitory protein I-κB in the cytoplasm. Following the 
appropriate signal from the inflammatory cytokine, I-κB becomes 
phosphorylated (mediated by IKK) and dissociates the NFκB complex. The 
free NFκB complex then translocates to the nucleus, binding appropriate 
response elements. This initiates the transcription of pro-inflammatory genes, 
eg. cytokines (IL-1β, TNFα, GM-CSF) chemokines (CXCL-8), adhesion 
molecules (ICAM-1). GR may interact with the p65 subunit, preventing it from 
activating the transcription machinery. Interestingly both the p65 and c-jun are 
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mutually antagonistic with the GR: their association with it hinders the GR 
binding to GRE thereby preventing the GC induced genes from expression. 
(Figure 6. [6, 43]). 
 
 
 
Figure 6.  
Mechanisms of cross-talk between the glucocorticoid receptor and NF-κB. The NF-κB 
transcription factor is composed of two subunits, p50 and p65 (RelA). The subunits are 
sequestered in the cytoplasm through the interaction of the inhibitory protein I-κB. Binding of 
proinflammatory cytokines to their appropriate receptors induces the activation of a kinase 
cascade leading to the phosphorylation of I-κB by inhibitory kinase (IKK). Phosphorylation of 
I-κB by IKK leads to the subsequent degradation of I-κB and release of the bound p65 and 
p50 subunits. The free NF-κB subunits translocate to the nucleus, dimerize, and bind NF-κB 
response elements to activate proinflammatory genes. The glucocorticoid receptor and the 
p65 subunit of NF-κB can physically interact and antago-nize each other's transcriptional 
activity. Several mechanisms have been proposed by which the physical interaction can lead 
to mutual antagonism: the glucocorticoid receptor and NF-κB may compete for coactivators 
SRC-1 (steroid receptor coactivator-1) and CBP (cAMP response element–binding protein 
(CREB)–binding protein) (direct binding coactivator competition); the cytoplasmic subunit of 
protein kinase A (PKA) may mediate the cross-repression of GR and NF-κB (PKA cross-talk); 
or the glucocorticoid receptor may directly or indirectly inhibit the phosphorylation and, thus, 
activity of RNA polymerase II (Pol II) on p65-occupied promoters (RNA Pol II inhibition). This 
GR-mediated inhibition prevents subsequent NF-κB–mediated gene transcription. Figure 
reproduced afte rNecela and Cidlowsky [6]. 
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1.1.11 GR interaction with STAT family proteins 
Proteins of the STAT-family participate in many signal transduction pathways 
initiated by cytokines of key importance such as IL-2 and IL-6. The activation 
of the STAT-proteins occur via the Janus kinase (JAK) [44]. Following 
phosphorylation by JAK, STAT-monomers dimerize and migrate into the 
nucleus. They regulate the transcription of a number of gene products 
controlling cell growth, survival, differentiation or apoptosis upon binding 
STAT responsive elements on DNA [44]. Numerous STAT-proteins are known 
to interact physically with GR, namely STAT-1, STAT-3 and STAT-5 (Figure 7, 
[6]). In general, the GR acts synergistically with the previously listed STATs. 
As a result of the interaction, GR and STATs enhance the expression of 
proteins regulated by STATs in a promoter-dependent way. Intriguingly, the 
STAT-family proteins regulate differently the transcription of genes controlled 
by the GR. For example, GR and STAT-3 synergistically increase the activity 
of the GR-responsive MMTV promoter and IL-6 responsive γ-fibrinogen and 
α2-macroglobulin genes in rat after IL-6 stimulus. In contrast, STAT-5 being 
activated after IL-2 stimulus and GR inhibits the MMTV promoter activity (GR 
responsive) and increases synergistically the expression of β-casein (STAT-5 
responsive) [45-48]. The interactions of the STAT-family proteins and GR 
highlight the existence of very diverse regulating mechanisms, which are 
recently not completely explored. It seems that GR-STAT interactions are not 
only to suppress but also to enhance the immune response in certain cases. 
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Figure 7. Cross-talk between the glucocorticoid receptor and the STAT family. Cytokines 
such as IL-2 and IL-6 activate STAT proteins through induction of the Janus kinase (JAK) 
pathway. JAK phosphorylates STAT proteins that exist as monomers in the cytoplasm. JAK-
mediated phosphorylation of STAT proteins induces their dimerization and translocation to the 
nucleus. The STAT proteins then bind response elements and regulate the expression of 
genes that influence growth, survival, apoptosis, host defense, stress, and differentiation 
functions. In some promoter contexts, the glucocorticoid receptor physically interacts with 
members of the STAT family such as STAT1, STAT3, and STAT5 (a and b), and 
synergistically enhances STAT-mediated gene expression. Reciprocally, STAT proteins can 
either enhance or repress GR-mediated gene activation depending on stimuli and the STAT 
protein involved. Figure reproduced after Necela and Cidlowsky [6] 
 
1.1.12 The regulatory role of GC mediated apoptosis in the 
immune system 
The robust anti-inflammatory effects of GCs are exerted not only via the 
down-regulation of pro-inflammatory signal transduction processes but also 
causing the apoptosis of cells participating in the inflammatory reaction. This 
pro-apoptotic effect was extensively studied in thymocytes, monocytes and 
eosinophil granulocytes. However, GC may promote also anti-apoptotic 
effects in some cells, which are exerted through the activation of Bcl-2 and 
NF-κB pathways [49]. Recent experimental data suggest that for the GC-
induced apoptosis an appropriate GR level is needed in the cell. If the GR 
expression is up-regulated after GC action, the result is apoptosis. This 
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phenomenon is characteristic for thymocytes and some T-cell lymphomas 
[50]. In contrast, when GC action is followed by GR down-regulation, (like in 
the majority of cells types) the cell is prevented from apoptosis [51]. 
1.1.13 The importance of the communication between GC and 
TcR signal transduction pathways 
One of the most intensively studied GC induced apoptosis process is the 
selection of thymocytes in the thymus. The maturation and selection of 
thymocytes is recently the subject of intensive debate. Nowadays the most 
acknowledged model is the “mutual antagonism theory” [51]. According to the 
aforementioned theory, the GC modifies the signal originating from the TcR, 
thereby preventing the cell from apoptosis. Thymocyte clones receiving none 
or “subthreshold” signal from the TcR will be deleted, (“death by neglect”) 
presumably via GC induced apoptosis [52]. TcRs with very strong affinity 
towards the self MHC-peptide complex are potentially autoreactive. This 
“super-strong” TcR-signal can not be antagonized by GCs, so these clones 
are deleted via negative selection [53]. 
The importance of GR is controversial in thymocyte selection. Some authors 
deny the role of GR in the thymic selection process, because the maturation 
of the thymocites seems to be undisturbed in the thymi of GR-deficient mice 
[54, 55]. This is supported by the fact that in the thymus the CD4+CD8+ 
double positive (DP) cells are the most sensitive to GC-induced apoptosis 
although expressing the lowest level of GR [56, 57]. Administration of GR-
antagonists do not influenced the GC effects on the thymic selection, 
suggesting a GR-independent process [56, 57].  
Mature peripheral T-cells after antigen recognition also have to “decide” 
between activation or anergy/apoptosis [58]. Many experimental data supports 
the opinion that the TcR is not a simple molecular on/off switch. Peptide 
ligands with varying affinity towards the TcR induce various “phosphorylation 
programmes” in T-cells [59]. Phosphorylation after engaging high affinity TcR 
ligands cause saturated CD3 ζ-chain phosphorylation (pp23 isoform 
dominates), the docking of phosphorylated ZAP-70 and the phosphorylation of 
the LAT adapter is saturated, too. If the TcR was stimulated by a low-affinity 
ligand, the unsaturated pp21 ζ-isoform dominated and ZAP-70 
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phosphorylation did not occur [59]. According to Van Leathem and colleagues, 
TcR stimulation with full agonist in the presence of GC induced a 
phosphorylation pattern similar to that of stimulation with partial agonist. They 
report that Dexamethasone (DX) treatment inhibited the phosphorylation 
signal after TcR stimulation. Since the DX treatment did not cause alteration in 
the expression level or in the activity of src-family kinases, they suggest that 
DX changed the membrane compartmentalisation of key signal-transduction 
molecules [60]. The authors propose that the GC administration abrogated the 
palmitoylation of important signalling molecules thereby inhibiting their raft-
association [61]. 
 
1.2 The signal transduction process originating from TcR 
1.2.1 The antigen recognition of T-cells 
The T-cell receptor (TcR) is the surface antigen receptor complex of the T-
cells being able to specifically recognise antigen. The antigen recognition of T-
cells is MHC-restricted, meaning that the TcR is only able to bind processed 
peptide antigens presented by the MHC complex. The antigen is not 
recognised by T-cells in its native form, but has to be taken up and processed 
by antigen presenting cells (APCs). The presented antigen can be either an 
endogenous protein degradation product of the APC itself or an exogenous 
antigen engulfed by phagocytosis. The endogenous peptides are presented 
via MHC Class I, the exogenous peptides are presented by MHC Class II. The 
MHC molecules of the APCs are recognised by CD8+ cytotoxic T-cells, and 
CD4+ helper T-cells, respectively [40]. 
1.2.2 Molecules participating in antigen recognition of T-cells 
While the TcR recognises the unique parts of the antigen-primed MHC, the 
constant domain of the MHC is also bound by to co-receptors on the surface 
of T-cells (CD4, CD8). The variable (V) domains of TcR show extreme high 
diversity, and every T-cell clone bears a TcR specific for different antigen. 
This makes up the T-cell repertoire which has enormous variability of antigen-
specific receptors. The TcR consists of a heterodimer of αβ or γδ chains the 
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CD3-complex, making up a functionally united molecular complex on the 
surface of the T-cells. Approximately 95% of the mature T-cells bear αβTcR, 
and 5% expresses γδTcR [40]. 
After antigen recognition by TcR, various signal transduction events occur 
involving the CD3-complex. Most of these proteins are members of the 
Immunoglobulin (Ig) superfamily, structurally consisting of globular Ig-
domains. These are approximately of 110aa length and held together by 
disulphide (S-S) bonds. The molecular weight of TcR α chain is of 43-49 kDa 
while β chain is of 38-44 kDa. They both have 2 extracellular domains, one 
variable (V) and one constant (C). The V domains show high structural 
homology with the variable domains of immunoglobulin molecules, containing 
the hypervariable or complementarity determining regions, (CDRs) which 
directly participate in antigen recognition. The cytoplasmic parts of the chains 
are rather short, 5-12 aa residues altogether, so the TcRαβ dimer without the 
CD3 complex is incapable of signal transduction [40]. 
The αβ T-cells can be further divided concerning their function: helper T-cells 
and cytotoxic T-cells, bearing CD4 or CD8 co-receptors, respectively. CD4 is 
the member of the Ig superfamily and consists of one polypeptide chain of 55 
kDa. It recognises Class II MHC molecules on the APCs. In humans CD4 is 
expressed by 2/3 of the peripheral T-cells, and monocytes, macrophages, 
dendritic cells are also CD4 positive. It is worth mentioning, that CD4 serves 
as the receptor of the Human Immunodeficiency Virus (HIV) gp120 envelope-
protein.  
The CD8 molecule is either a homodimer (CD8αα chains) or a heterodimer 
(CD8αβ). It associates with Class I MHC molecules thereby stabilizing the link 
between the T-cell and the APC. Both CD4 and CD8 molecules contain 
characteristic CXC motives in their cytoplasmic part allowing the association 
with the p56-lck kinase, a src-family kinase present in T-cells [40].  
1.2.3 The structure and function of the CD3 complex 
Because the short intracellular parts of the TcR chains are incapable of signal 
transduction, other molecules perform the transmission of the signals 
following antigen recognition. It became evident soon that the chains of the 
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CD3 complex play this role. This is confirmed by the fact that crosslinking the 
CD3 complex with antibodies leads to T-cell activation [62]. The CD3 complex 
is expressed on the surface of every T-cell. The complex consists of multiple 
chains, associated with each other and with the TcR with non-covalent bonds. 
The chains of the CD3 complex are termed γ, δ, and ε chains and there are 
either homodimeric (ζ−ζ) or heterodimeric (ζ−η) chains. The γ, δ, and ε chains 
have an extracellular Ig-like domain and a relatively long intracellular part with 
a so-called ITAM sequence (Immunoreceptor Tyrosine-based Activation 
Motif), while the ζ chains have 3 ITAM sequences. The ITAM tyrosines 
become phosphorylated by various kinases upon the signal transduction 
events and may serve as docking sites for other signalling molecules. The 
ITAMs are present not only in T-cells but also other cells and molecules, such 
as B-cell receptor, Fc-receptors and cytokine receptors [40]. 
1.2.4 Signal transduction events following antigen recognition in 
T-cells 
The first signal transduction events following the antigen recognition by the 
TcR are the tyrosine phosphorylation of various molecules, which only needs 
a couple of seconds to occur. This activation signal triggers such biochemical 
events, which cause a significant change in the metabolism of T-cells. In two 
hours the activated T-cells express cytokine receptors and cytokines (the 
most characteristic is the IL-2 and its high-affinity receptor). Within 2-6 hours 
further cytokines are synthethised which is followed by DNA replication in 24 
hours. Mitosis occurs within 48 hours [63]. The optimal T-cell activation 
requires the participation of a number of co-receptors and adhesion 
molecules. These are responsible for the stabilisation of the connection 
between T-cells and APCs, as well as providing co-stimulatory signals, which 
are indispensable for achieving physiological T-cell response to the antigen. 
One of the earliest events following the antigen recognition by the TcR is the 
activation of the src-family kinases. The most studied src-kinases in T-cells 
are the p56-lck and p59-fyn associated with CD4/8 or with CD3 complex, 
respectively. Although they are structurally highly homologous, the p56-lck 
plays a role in the T-cell activation process, while the p59-fyn rather delivers 
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inhibitory/anergizing signals. Src-family kinases contain 3 domains, the SH3 
domain on the N-terminus, which recognises proline rich regions on other 
proteins, the SH2 domain, which associates with phosphorylated tyrosine and 
the C-terminal kinase domain. Both the p56-lck and p59-fyn has a 
myristoylation signal in their N-terminus. The conjugation with myristyl acid 
containing long hydrophobic chain enables these molecules to permanently 
associate with lipid rafts in the membrane. The activity of src-family kinases is 
regulated by tyrosine phosphorylation. There are two main phosphorylation 
sites in src kinases: an N-terminal inhibitory site and a C-terminal activating 
site [64]. 
The chains of the CD3 complex, mainly the ζ chains become phosphorylated 
after antigen recognition. This phosphorylation is mediated by the p56-lck 
kinase. The phosphotyrosines serve as a docking site for ZAP-70 kinase 
(zeta-chain associated protein of 70 kDa). The chains of CD3 complex, 
together with src-family kinases and many other signalling molecules are the 
part of the so-called “immunological synapse”.  
Membrane lipid rafts are cholesterol-rich parts of the cell membrane which 
have key role organising the immunological synapse formed between the T-
cell and the APC. All of the signalling molecules participating in T-cell 
activation have a strict spatiotemporal organization schedule regardless they 
are excluded or included the lipid rafts. If this process is disturbed, the 
molecules can not reach their correct spatiotemporal position/conformation 
and the proper T-cell activation is prevented. [65-67] 
1.2.5 The role of ZAP-70 kinase in T-cell activation 
The ZAP-kinase is a T-and NK cell specific kinase of the Syk family. It is 
essential for proper T-cell development and function. In the absence of active 
ZAP-70 the thymocyte development is arrested at the DP stage in mice and 
there are no mature αβT-cells in the periphery [68]. Both negative and positive 
selection is severely perturbed in ZAP-70-/- thymocytes. The reconstitution of 
these mice with human ZAP-70 restored the block in T-cell maturation and 
allowed the appearance of mature SP thymocytes and peripheral T-cells [69]. 
ZAP-70 deficiency in humans results in Severe Combined Immunodeficiency 
syndrome (SCID). SCID is a heterologous syndrome affecting both T and B-
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cell function. SCID due to ZAP-70 deficiency is characterized by the lack of 
CD8+ T-cells either in the thymus and periphery. Peripheral CD4+ T-cells fail 
to mobilize calcium after anti-CD3 activation and do not proliferate in response 
to phytohemagglutinin or concanavalin-A (both lectins induce TcR-dependent 
proliferation) [70, 71]. Interestingly, phosphorylation of near-TcR molecules 
occur not only after TcR stimulation. It is known that ZAP-70 participates in 
CD27/CD70 [72], CD59 [73], CD44 [74], RANTES chemokine [75], CD26 [76], 
CD38 [77], CD5 [78], LFA-1 [79], CD28 [80], CXCR4 [81] and Fas/Fas-L [82], 
signal transduction pathways. We recently found that the glucocorticoid 
hormone may interfere to TcR signal transduction via the p56-lck/ZAP-70 
kinase hierarchy [83]. 
 
 
Figure 8. The ribbon diagram of human ZAP-70 showing the known phosphorylated 
tyrosine residues  
 
Structurally the ZAP-70 kinase consists of two tandem SH2 domains and one 
C-terminal kinase domain (Figure 8). The ZAP-70 plays a crucial role 
transducing the signal derived from the TcR. After the TcR and the co-
receptors (CD4 or CD8) engaged the MHC-antigen complex, the src-family 
kinases (primarily p56-lck) become activated and phosphorylate the tyrosine-
containing ITAMs on the CD3 complex. These phosphorylated tyrosines 
provide docking sites for ZAP-70 kinase by its SH2 domains. Then the ZAP-
70 itself is also phosphorylated by src-family kinases [84]. The ZAP-70 has 
two major substrates: LAT and SLP-76 adaptor proteins. LAT is a 
transmembrane adaptor protein, being phosphorylated on a number of 
tyrosine residues. Phosphorylated LAT molecules serve as docking platform 
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for other signalling proteins. There is a myristoilation motif on the N-terminus 
of LAT: the hydrophobic group ensures its association with the membrane 
lipid rafts [67]. SLP-76 is a cytoplasmic adaptor protein containing several 
phosphorylation sites. It also has a proline-rich region which allows the 
attachment of proteins with SH3 domain and a SH2 domain, which binds to 
phosphotyrosines on other proteins [85, 86]. The LAT and SLP-76 initiates a 
“molecular scaffold system” which provides platform in the cytoplasm for 
signalling molecules. These adaptor proteins and other signalling molecules 
provide a complex system which is highly organized to allow the fine tuning of 
the signalling processes which will result in T-cell activation.  
1.2.6 The activity regulation of ZAP-70   
The activity regulation of ZAP-70 and other proximal kinases is crucial: the 
pattern of near-TcR tyrosine phosphorylation depends on the “strength” of 
signal (antigen affinity towards the TcR) and thus determines the fate of the T-
cell after antigen encounter: activation, anergy or apoptosis [59]. The activity 
regulation of the non-receptor PTKs occur mainly via phosphorylation. There 
are 30 tyrosine residues in ZAP-70 and 11 of them are known phosphorylation 
sites (Figure 8). Initial studies on TcR signalling revealed that the 
phosphotyrosine-content as well as the kinase activity of ZAP-70 increases 
rapidly after TcR stimulation [87]. The recently known tyrosine 
phosphorylation sites and literature data are summarized in Table 2. and 
briefly explained in the following sections.   
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Tyrosine 
on ZAP-70 
Phosphorylation 
Induced by 
Function Literature 
Y69 In vitro: 
p56-lck 
unknown [88] 
Y126 In vitro: 
autophosphorylation 
p56-lck 
unknown [88] 
Y178 In vitro: 
p56-lck 
unknown [88] 
Y292 In vitro: 
autophosphorylation 
p56-lck 
OKT-3 activation 
Docking site for 
Cbl (inhibition) 
[88] 
[89] 
[90] 
[91] 
[92] 
[93] 
Y315 Autophosphorylation 
Phosphorylated upon 
TcR triggering 
Docking site for 
Vav 
Docking site for 
CrkII 
Allosteric 
regulation for 
SH2- ITAM 
binding 
[94] 
[92] 
[95] 
[96] 
[97] 
Y319 Autophosphorylation 
Phosphorylated upon 
TcR triggering 
Docking site for 
p56-lck SH2 
domain 
[98] 
[99] 
[100] 
[96] 
Y474 TcR triggering Docking site for 
Shc 
[101] 
Y492 p56-lck 
in vitro  
Inhibitory site [102] 
[89] 
Y493 p56-lck 
in vitro  
Phosphorylation 
dependent 
activation 
[102] 
[103]  
[89] 
Y597 autophosphorylation Negative 
regulatory site 
[104] 
Y598 autophosphorylation Negative 
regulatory site 
[104] 
 
Table 2. Summary of the ZAP-70 tyrosine phosphorylation sites 
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1.2.7 N-terminal tyrosine phosphorylation sites of ZAP-70 
Initially, Watts and colleagues identified some phosphorylation sites analyzing 
the tryptic fragments of ZAP-70 from Jurkat cells by electrospray ionization 
mass spectrometry [88]. Others detected different phosphorylation sites 
applying cyanogen-bromide cleavage. [98]  
There is only one publication which identifies three N-terminal phosphorylation 
sites on ZAP-70: Y69, Y126 and Y178 [88]. There are no further information 
about the function of these phosphorylation sites. The Y69 site is located 
within the N-terminal SH-2 domain of ZAP-70. Although the sequence around 
this site in human ZAP-70 is highly homologous not only to that of in murine 
ZAP-70, but also to murine and human Syk, this tyrosine residue has not been 
shown being phosphorylated in murine Syk [105].  
The Y126 site is located within the Interdomain A region of ZAP-70 kinase. 
The homologous tyrosine Y130 is phosphorylated in murine Syk kinase [105]. 
The phosphorylation of this tyrosine inhibits the association of Syk kinase with 
the ITAMs of the B cell antigen receptor complex. [106, 107] However, we 
have no information about the exact function of this tyrosine in ZAP-70.  
The Y178 is located in the C-terminal SH-2 domain of ZAP-70. It’s function is 
unknown, Watts and colleagues showed that it is phosphorylated in vitro in the 
presence of p56-lck [88]. Magistrelli et al. described that the ablation of the 
SH2 domains of ZAP-70 (thus abolishing all three aforementioned 
phosphorylation sites) increases the catalytic activity of ZAP-70 [108]. 
 
1.2.8  Phosphorylation sites located on Interdomain B of ZAP-
70 
The phosphorylation sites of interdomain B region were studied the most 
intensively. This region is important in the regulation of ZAP-70 intrinsic kinase 
activity as well as the intermolecular interactions with other signalling proteins. 
Watts et al. designated the Y292 as the principal autophosphorylation site of 
ZAP-70 [88]. It is known that this is the docking site of the Cbl protein which 
negatively regulates ZAP-70 function. [109, 110]. The pY292 phosphotyrosine 
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can be dephosphorylated by LMPT phosphatase, thus activating ZAP-70 [93]. 
Interestingly, when the interdomain B region is entirely removed containing 
the Y292, Y315 and Y319 phosphorylation sites, the mutated ZAP-70 retained 
full receptor binding affinity. Although the intrinsic kinase activity was markedly 
decreased, the cells transfected with the mutant ZAP-70 showed NF-AT 
induction, calcium signal and MAPK cascade activation [111]. 
The first in vitro functional studies of the of the Y315 phosphorylation site were 
performed by Wu and colleagues. They demonstrated that pY315 recruits the 
95 kDa protooncogene product Vav. A Y>F mutation introduced at this site 
eliminated the ZAP-70-Vav interaction and caused deep impairment in T-cell 
activation. Moreover, this point mutation caused a marked reduction in the 
tyrosine phosphorylation of ZAP-70, Vav, SLP-76, and Shc [94]. Recent 
findings indicate, that the pY315 serves also for binding the CrkII adaptor 
protein [97]. The authors found that the CrkII and Vav binds to pY315 with 
affinity of similar magnitude. They propose that the two different signalling 
protein may link ZAP-70 to different signalling pathways. However, the exact 
role of the ZAP-70-CrkII linkage is not determined yet [97]. 
The Y319 functions as an important activating phosphorylation site on ZAP-
70. The first in vitro study by DiBartolo et al. suggested that the 
phosphorylation of this site is induced both by autophosphorylation and by 
TcR stimulation. The Y319F mutation dramatically impaired anti-TcR-induced 
activation of the NF-AT and IL-2 production of T-cells. Additionally, substantial 
loss was observed in ZAP-70-(Y319F) activation-induced tyrosine 
phosphorylation and up-regulation of catalytic activity, as well as a decreased 
capacity to phosphorylate known ZAP-70 substrates, such as SLP-76 and LAT 
[98]. Later it was shown that this tyrosine is responsible for mediating the 
ZAP-70 co-clustering with p56-lck [99]. There are also data about CTLA-4 
mediated suppression: the ligation of CTLA-4 selectively inhibited the 
phosphorylation of Y319 of ZAP-70 [100].  
Hitherto there are three in vivo studies designed to elucidate the regulatory 
functions of the Interdomain B phosphorylation sites on ZAP-70. DiBartolo and 
colleagues demonstrated that the pY315 may function as an allosteric 
regulator for the SH2-ITAM association. Studying knock-in mice expressing 
the point mutant ZAP-70-(Y315F) they showed that the affinity of mutant ZAP-
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70 is markedly decreased towards the ITAMs compared to wild type ZAP-70. 
Moreover, the authors found decreased phosphorylation of the TcR ζ chain, 
suggesting that the phosphotyrosines were more accessible to phosphatases. 
However, the defective ITAM-binding of the Y315F mutant ZAP-70 appeared 
to be independent of this residue being the binding site of Vav [95]. Magnan 
and co-workers generated mice with Y292F and Y315F mutations. The thymi 
of all transgenic mice showed normal cellularity and thymocytes appeared to 
have normal surface marker expression. Analyzing the signalling processes 
derived from the TcR the authors observed various phosphorylation changes 
both in the ZAP-70-(Y315F) and ZAP-70-(Y292F) mutant mice. Referring to 
the complex function of ZAP-70 during the T-cell maturation stages marked 
differences were described between the signalling processes in thymocytes 
and peripheral T-cells in both mutants. In general, the ZAP-70-(Y292F) mutant 
mice were “hypersensitive” to TcR stimulation showing increased 
phosphorylation and producing more IL-2 and IFNγ in response. In contrast, 
ZAP-70-(Y315F) mutant mice showed reduced rate of positive selection and 
delayed negative selection indicating the attenuated ZAP-70 function [92]. The 
other study by Gong Q et al. used transgenic mice expressing the Y315F and 
Y319F mutants of ZAP-70 under the control of the lck promoter. The authors 
described that CD4+ thymocytes were present in a significantly lower number 
in the thymus and both CD4+ and CD8+ cell number was lower in the 
peripheral lymphoid organs of the ZAP-70-(Y319F) mutant mice, than that of 
in the wild type controls. The thymocytes obtained from the ZAP-70-(Y319F) 
mutant mice showed attenuated calcium signal responding TcR stimulation. 
The results of this group showed on ZAP-70-(Y315F) mutant mice are 
consistent with those of the former group showed [96]. 
1.2.9  C terminal tyrosine phosphorylation sites of ZAP-70 
The tyrosine residue 474 was identified as the binding site of Shc, which 
couples the activated TcR to Ras. Y>F point mutation of this site prevented 
ZAP-70 interaction with Shc and the subsequent binding of Shc to phospho-ζ. 
Neither ZAP-70 catalytic activity nor the pattern of protein phosphorylation 
induced by TcR triggering was affected by this mutation. However, expression 
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of the ZAP-70-(Y474F) mutant resulted in impaired TcR-dependent gene 
activation [101]. 
Tyrosine 492 and 493 as a phosphorylation site was first identified by Watts et 
al. [88]. First characterisation of the ZAP-70-(Y492F) point mutant showed 4 
times higher basal kinase activity compared to wild type ZAP-70, [102] while 
the phosphorylation of the Y493 site was required for proper ZAP-70 
activation mediated by p56-lck [103]. 
Virtually all PTKs are themselves substrates for tyrosine phosphorylation. In 
some PTKs, such as the Src family, there are tyrosine residues located 
outside of the kinase domain, which inhibit kinase activity when 
phosphorylated. Usually these tyrosines are the substrates of other regulatory 
PTKs. Other tyrosine residues present in the kinase domain of all PTKs are 
critical for full activation of the kinases [112]. Phosphorylation sites like this 
were first characterised in Src kinase. Here the tyrosine residue Y416 is the 
principal site of autophosphorylation with the sequence EY416TAR. Highly 
homologuos phosphorylation site in p56-lck kinase is EY394TAR [113]. The 
amino acids around the corresponding tyrosine of the human and murine 
ZAP-70 sequence are homologous, too: SY492Y493TAR. Strikingly, the Syk 
DENY525Y526KAG sequence around the corresponding phosphorylation site is 
different. This difference may cause the phenomenon that the ZAP-70 by itself 
is not active after being recruited to the TcR ζ ITAMs, but it needs to be 
phosphorylated by src family kinases (mainly by p56-lck) to achieve fully 
activated state. In contrast to ZAP-70, Syk kinase is able to autophosphorylate 
this residue once docked on the ITAMs, not requiring the presence of src 
family kinases [114]. 
Negative regulatory sites have been found in the C-terminal end of ZAP-70 by 
Zeitlmann and colleagues [104]. Consistently with the C-terminal tyrosines 
Y628, Y629 and Y630 of the Syk kinase, the adjacent tyrosines Y597 and 
Y598 of ZAP-70 exert a negative regulatory function when phosphorylated. 
Y>F mutations of these sites result in a prominent gain-of-function phenotype 
in Jurkat T cells, as increased cytokine promoter activation, elevated tyrosine 
phosphorylation of potential targets and augmented intracellular calcium 
mobilization [104]. 
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2 Objectives 
 
1. Studying the rapid non-genomic GC effects on T-cells using an in vitro 
cultured model cell line (Jurkat). Definition the alterations in the tyrosine 
phosphorylation pattern in Jurkat cells after high dose Dexamethasone 
(DX, GR agonist) treatment. 
2. Characterisation of the rapid changes in the phosphotyrosine content of 
ZAP-70 kinase after high dose DX treatment. Determination of the GR 
dependency and the upstream kinase responsible for DX induced 
phosphorylation of ZAP-70. Studying the kinetics of the DX induced 
ZAP-70 phosphorylation. 
3. Examination the possible physical linkage between GR and ZAP-70 
using co-immunoprecipitation and confocal microscopy in the presence 
and absence of GR agonist in Jurkat cells. Clarification the relationship 
of the Hsp-90 chaperone toward the GR and ZAP-70. 
4. Studying the relation of GR, ZAP-70 and Hsp-90 in a non-T cell 
environment applying HeLa cells stably transfected with ZAP-70.  
5. Investigation of the crosstalk between the TcR-CD3 complex and GR-
related signal transduction pathways.  
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3 Experimental procedures 
3.1 Cell lines 
We used Jurkat cells (human acute T-cell leukemia) and its p56-lck and ZAP-
70 deficient subclone (JCaM1.6 and P116, respectively), a kind gift of E. 
Monostori (Biological Research Centre, Szeged, Hungary), and HeLa cells 
(human cervix adenocarcinoma). Cells were cultured in humidified 
atmosphere, containing 5 % CO2 at 37oC, in RPMI medium supplemented 
with 5 % (Jurkat cells) and 10 % (JCaM1.6 and HeLa cells) fetal calf serum 
(Gibco).  
3.2 Plasmid construct 
Human full-length wild-type ZAP-70 cDNA has been cloned, sequenced and 
inserted in the pWPTS lentiviral transfer plasmid. In this construct ZAP-70 is 
under the control of an EF1 promoter. This late second generation lentiviral 
construct contains elements that increase transgene integration and 
expression, i.e. cPPT and WPRE [115, 116]. 
3.3 Lentivirus production and transduction 
Briefly, an envelope construct (pMD.G), a packaging plasmid (R8.91) and the 
transfer plasmid (pWPTS with EF1-ZAP-70) were transiently co-transfected by 
calcium-phosphate method into 293T cells pre-treated with chloroquine (1mM 
final concentration). Following an overnight incubation and medium change, 
the supernatant of the virus producing cells was harvested after 24 hours, 
centrifuged (2000 rpm, 10 min, 4°C) and filtered (0.45mm pore-size PVDF-
coated filters) to eliminate rough cellular debris [117-119]. P116 and HeLa cell 
lines cells were transduced by spinoculation. Briefly, viral supernatants were 
spun in 24-well plates (3600 rpm, 60 min, 4°C), then the supernatant was 
discarded and 20,000 cells were carefully layered into the wells in 2 ml fresh 
medium. The viral supernatant was previously titrated and biological viral titer 
was approx. 105 TU/ml. P116 and HeLa cell lines were transduced at MOI=10 
(MOI: multiplicity of infection or virus/cell ratio) [120]. 
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3.4 Chemicals and buffers 
All fine chemicals were purchased from Sigma-Aldrich otherwise indicated. 
Dexamethasone as a glucocorticoid hormone receptor agonist and RU486 
(Mifepristone) was used as glucocorticoid antagonist, both dissolved in DMSO 
at a concentration of 10 mM. For Western-blot experiments cells were lysed in 
lysis buffer (50 mM HEPES, 10 mM sodium pyrophosphate 10 mM EDTA, 100 
mM sodium fluoride, 10 % glycerol, 1 % Triton X-100) or, in case of the co-
immunoprecipitation experiments, we used TEM buffer containing 50 mM 
NaCl, 10 mM Tris-HCl pH7.6, 4 mM EDTA, 20mM sodium molybdate, 10 % 
glycerol. Aprotinin, leupeptin (Fluka) (10 µg/ml), PMSF (2 mM) were freshly 
added to the lysis buffers.  
The samples were separated by SDS-PAGE after adding 2x sample buffer 
(125 mM Tris pH 6.8, 4 % SDS, 10 % glycerol, 0.006 % Bromo-phenol-blue 
10 % mercaptoethanol). To saturate non-specific binding sites, the blots were 
soaked in blocking buffer (1 % bovine serum albumin, 10 mM Tris, 100 mM 
sodium chloride, 0.1 % Tween 20, pH 7.4)  For washing the blots washing 
buffer was used (10 mM Tris, pH 7.4 100 mM sodium chloride, 0.1 % Tween-
20). Western-blot visualisation was performed by enhanced 
chemiluminescence as described in the manufacturer's instructions 
(SuperSignal West Pico Chemiluminescent substrate, Pierce). The 
intracellular labelling for confocal microscopy was performed in saponine 
buffer (0.1% saponin, 0.1%BSA, 0,1% azide in PBS).  
3.5 Antibodies 
We used mouse monoclonal anti-human CD3 antibody (clone: OKT-3, 2,5 
mg/ml stock solution in PBS) for cell activation. Immunoprecipitation was 
performed either with rabbit polyclonal anti-ZAP-70 antibody (kindly provided 
by E. Monostori, Biological Research Centre, Szeged, Hungary), or mouse 
monoclonal anti-GR antibody (clone 8E9) produced in our laboratory [121]. 
For western blotting mouse monoclonal anti-ZAP-70 (clone: 29, Transduction 
Laboratories) mouse monoclonal anti-GR antibody (clone 5E4, [121]), rabbit 
polyclonal anti-Hsp-90 antibody (Santa Cruz Biotechnology), HRPO-
conjugated goat anti-mouse IgG (Hunnavix). For confocal microscopy 
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fluorescein conjugated anti-GR (5E4) and phycoerythrin-conjugated mouse 
monoclonal anti-ZAP-70 (eBioscience, clone 1E7.2) were used. FITC and PE-
conjugated mouse IgG1 isotype control antibodies (DakoCytomation) were 
applied as negative controls. The tyrosine-phosphorylation pattern was 
examined by using biotinylated monoclonal anti-phosphotyrosine antibody 
(clone: PY20, Transduction Laboratories) and HRPO-conjugated streptavidin 
(Amersham) as a secondary reagent. To prove the equal protein loading we 
used monoclonal mouse anti-β-actin antibody (Sigma).  
3.6 Geldanamycin treatment 
Jurkat cells were incubated overnight in complete RPMI medium in the 
presence of 1,78 µM Geldanamycin or solvent (DMSO). After the incubation 
cells were washed once in serum-free RPMI and subjected to DX treatment 
as indicated below. 
3.7  Glucocorticoid analogue/antagonist treatment   
Jurkat or JCaM1.6 cells were harvested and resuspended in incomplete 
RPMI. The cells were plated and incubated for 4 hours at 37oC in the 
presence or absence of RU486 (Mifepristone). After a washing step, final cell 
concentration was set to 108cells/ml and tubes were placed on an Eppendorf 
Thermomixer set at 37oC. Dexamethasone (DX) or solvent (DMSO) were 
added at a concentration of 10µM for 5 minutes. The treatment was stopped 
by placing the tubes into liquid nitrogen. In case of confocal microscopy 
samples the final cell concentration was 107cells/ml and the DX treatment was 
stopped by addition of 9 volumes of ice-cold PBS supplemented with 0.1% 
sodium-azide.  
3.8  Cell activation and lysis 
50 µg OKT-3 anti - CD3 monoclonal antibody was added to the DX treated or 
untreated samples. Following incubation for the indicated time at 37oC the 
activation was stopped by quickly freezing the cells in liquid nitrogen. Then the 
samples were lysed for 30 minutes in 500 µl ice-cold TX-100 or TEM lysis 
buffer. When TEM buffer was used for co-immunoprecipitation experiments, 
an additional sonication step was included for 5 times 5 seconds at 5W power. 
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After lysis the samples were centrifuged at 13000 rpm for 15 minutes at 4oC. 
Postnuclear supernatants were aspirated and boiled for 5 minutes with equal 
amounts of 2x sample buffer or subjected to immunoprecipitation. 
3.9  Immunoprecipitation and Western blot 
Equal amounts of cell lysates were incubated on a rotator platform at 4oC with 
30 µl slurry of Protein G coupled Sepharose beads (Amersham) for 30 
minutes. After the removal of the pre-clearing beads, 10 µl precipitating 
antibody was added to the lysates for 2 hours. Then Protein-G Sepharose 
beads were added for additional 2 hours. The beads were pelleted and five 
washes were performed with ice-cold washing buffer. After washing, beads 
were resuspended in 100 µl of SDS sample buffer and the 
immunoprecipitates were boiled for 10 minutes. The supernatants were 
collected and loaded on SDS-polyacrylamide gels. SDS-PAGE was performed 
using a BioRad MiniProtean elecrophoresis equipment. The gels were blotted 
overnight to nitrocellulose membranes (Bio-Rad) by wet transfer procedure. 
After blocking non-specific binding sites for 1 hour, blots were incubated with 
the primary antibody for two hours. Following 3x 10 minutes washing, the 
HRPO - conjugated secondary antibody or streptavidine was added for one 
hour. Western blots were visualised with SuperSignal West Pico 
Chemiluminescent substrate and the fluorescent signal was recorded using X-
ray film. (Fujifilm).  
3.10  Confocal microscopy 
Dexamethasone treated or untreated Jurkat cells were fixed for 10 minutes in 
4 % paraformaldehyde, washed once in ice-cold PBS-azide and once in 
saponine buffer. The cells were permeabilized in saponine buffer and the 
fluorochrome labelled monoclonal antibodies or the appropriate negative 
control antibodies were added at a concentration of 1 µg/ml. After one hour 
incubation on ice the cells were washed twice in saponine buffer, once in 
PBS-azide and layered onto slides. After the cells settled the remaining fluid 
was carefully aspirated and the slides were covered using 50 % glycerol-PBS. 
In case of HeLa cells the labeling procedure was carried out on monolayers 
grown on coverslips. An Olympus Fluoview 300 confocal microscope or later a 
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Olympus Fluoview FV1000S-IX81 system was used for the examination of the 
samples. 
3.11  Calcium signal measurement  
Intracellular free calcium was measured using Fluo-3 AM according to the 
protocol previously described [122], with some modifications [123]. Briefly: the 
fluorescence intensity of Fluo-3 AM dye was detected in the gated cell 
population at 526 nm (FL1 channel), which is proportional with the intracellular 
free calcium level [122]. After measuring basal fluorescence at 526 nm, anti-
CD3 antibody was added to the tubes (each containing 5x105 cells/500 µl 
RPMI, loaded by Fluo-3 AM for 30 min at RT prior to analysis) and the 
measurement was continued for a further 400 s, thus making possible to 
follow the alterations of intracellular free calcium level (FL1 fluorescence 
intensity) in time. Gates were created along the time axis of the activation dot 
plots at definite time points and the mean fluorescence intensity at 526 nm 
was statistically analyzed from every gate. These values were corrected with 
the basal fluorescence intensities measured in the same sample before the 
addition of the activating agent and represented as mean fluorescence 
intensity ratios (y-axis) [123].  
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4 Results 
4.1 Dexamethasone alters the tyrosine phosphorylation 
pattern of Jurkat cells 
First we examined how DX treatment influences the tyrosine-phosphorylation 
pattern of resting and anti - CD3 activated Jurkat cells. 2 minutes of 10µM DX 
treatment alone caused increased protein tyrosine - phosphorylation at the 
34, 52, 59, 70 and 90 kDa molecular weight bands in whole Jurkat cell 
lysates, compared to the solvent-treated control (Figure 9.). Activation with 
monoclonal anti - CD3 antibody markedly increased the tyrosine-
phosphorylation of several proteins in whole cell lysates at 25, 34, 38, 40, 52, 
59, 70 and 90 kDa molecular weight ranges, respectively (Figure 9.). A 2 
minute DX pre-treatment at 10 µM concentration inhibited the anti - CD3 
induced tyrosine-phosphorylation the proteins of 34, 38, 40, 52, 59, and 90 
kDa (Figure 9.). No significant signal was detected on negative control blots, 
incubated with biotinylated monoclonal anti-insulin antibody (data not shown). 
 
4.2 Dexamethasone rapidly induces ZAP-70 phosphorylation  
ZAP-70 plays a central role in the TcR signal transduction pathway, by 
phosphorylating a multiple substrates, and itself is also phosphorylated on 
several tyrosine residues. For this reason we investigated the tyrosine-
phosphorylation of ZAP-70 after DX and / or anti - CD3 treatments. 5 minutes 
exposure to 10 µM DX caused an average of 4 fold (3.32 + 1.72) increase in 
tyrosine-phosphorylation of the ZAP-70 kinase in the anti-ZAP-70 precipitated 
samples (Figure 10.). The anti - CD3 treatment also resulted in a 4 fold 
increase (3.59 + 1.69) in the tyrosine-phosphorylation of ZAP-70 kinase 
(Figure 10.). The tyrosine-phosphorylation after combined DX + anti - CD3 
treatment was higher (4.98 + 2.83) than in case of anti - CD3 or DX treatment 
alone (5 fold versus 4 fold increase, respectively). Phosphorylation increase 
after single DX or anti - CD3 or combined treatments proved significant 
compared to the solvent treated control sample (Student’s t-test, P < 0.05). 
We observed higher phosphorylation after combined DX + anti - CD3 
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treatment than single DX or anti - CD3 treatment in all of our independent 
experiments, but this further rise was statistically not significant by Student’s 
t-test.  (Figure 10.).  
 
 
 
 
 
Figure 9.. Dexamethasone 
and / or anti - CD3 treatment 
influenced the tyrosine-
phosphorylation pattern in 
Jurkat cell lysates. Western 
blotting was performed with 
monoclonal anti-
phosphotyrosine antibody. 
Then the blot was stripped and 
reprobed with monoclonal anti-
beta actin antibody to check 
equal protein loading.  
Molecular weight markers are 
indicated on the left, treatment 
modalities on the bottom side 
of the blot. The experiment 
was repeated three times with 
similar results. Here a 
representative Western blot is 
depicted. 
Figure 10.  
Effect of Dexamethasone and / 
or anti-CD3 treatment on ZAP-70 
tyrosine-phosphorylation. 
Western blotting was performed 
on anti-ZAP-70 immuno-
precipitated (IP: a-ZAP-70) 
samples with anti-
phosphotyrosine antibody (IB: a-
PY) (Panel A). The blots were 
stripped and reprobed with 
monoclonal anti-ZAP-70 antibody 
(IB: a-ZAP-70) (Panel B). The 
relative phosphotyrosine content 
of ZAP-70 is shown as relative 
density averages + SD from the 
densitometry data of three 
separate experiments (* P < 
0.05) (Panel C). Treatment 
modalities are indicated below 
the diagram (Panel C). 
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4.3 Time kinetics of Dexamethasone induced ZAP-70 
phosphorylation 
Since the kinetics of tyrosine-phosphorylation is a key feature to understand 
cellular signalling events, we further investigated the time course of DX 
induced ZAP-70 tyrosine-phosphorylation. The tyrosine-phosphorylation of 
ZAP-70 occurs rapidly after the addition of high dose DX. We measured a rise 
in tyrosine-phosphorylation after 1 and 2 minutes after DX administration, 
respectively (Figure 11.). Dephosphorylation occurred within 5 minutes 
(Figure 11.).  
 
Figure 11. Time dependent tyrosine-phosphorylation of ZAP-70 after high dose 
Dexamethasone treatment. Western blotting was performed on anti-ZAP-70 
immunoprecipitated (IP: a-ZAP-70) samples with anti-phosphotyrosine antibody (IB: a-PY) 
(Panel A). The blots were stripped and reprobed with monoclonal anti-ZAP-70 antibody (IB: 
ZAP-70) (Panel B). Duration of the Dexamethasone treatment is indicated below the figure. 
The experiment was repeated three times with similar results. 
 
 
4.4 Dexamethasone induced ZAP-70 phosphorylation is p56-
lck dependent 
In addition to acting as a tyrosine kinase, ZAP-70 is a substrate of p56-lck, a 
T-cell specific src-family tyrosine kinase. We therefore tested whether the DX-
induced rapid tyrosine-phosphorylation of ZAP-70 was p56-lck dependent. 
When JCaM1.6, the p56-lck deficient subclone of Jurkat cells was subjected 
to high dose DX treatment, we observed no rise in the degree of tyrosine-
phosphorylation of ZAP-70 kinase (Figure 12.). The anti - CD3 activation 
induced notable increase in tyrosine-phosphorylation of ZAP-70 in JCaM1.6 
cells (Figure 12.). Additional DX stimulation did not alter the phosphotyrosine 
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increase caused by anti - CD3 activation in the p56-lck deficient cell line 
(Figure 12.). 
 
 
 
Figure 12. ZAP-70 tyrosine-phosphorylation after Dexamethasone and / or anti - CD3 
treatment in p56-lck kinase deficient Jurkat subclone JCaM1.6. Western blotting was 
performed on anti-ZAP-70 immunoprecipitated (IP: a-ZAP-70) samples with anti-
phosphotyrosine antibody (IB: a-PY) (Panel A). The blots were stripped and reprobed with 
monoclonal anti-ZAP-70 antibody (IB: ZAP-70) (Panel B). Treatment modalities are indicated 
below the blots. A representative Western blot is shown from 3 independent experiments with 
similar results. 
 
4.5 Dexamethasone triggered ZAP-70 phosphorylation is 
abolished by RU486 pre-treatment 
Previous studies indicated the existence of various GR mediated or receptor 
independent non-genomic GC effects. Therefore we investigated whether DX 
induced tyrosine-phosphorylation alterations were GR dependent in Jurkat T-
cells using RU486 (Mifepristone), a glucocorticoid receptor antagonist. DX 
alone caused markedly growth in the tyrosine-phosporylation of ZAP-70 
(Figure 13.). Pre-treatment of Jurkat cells for 4 hours with equimolar RU486 
prevented this rapid phosphorylation of ZAP-70 induced by subsequent high 
dose DX exposure. RU 486 treatment alone caused no remarkable tyrosine-
phosphorylation change in ZAP-70 (Figure 13.). 
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Figure 13. Effect of RU486 (Mifepristone, glucocorticoid receptor antagonist) pre-treatment 
on the Dexamethasone induced tyrosine-phosphorylation of ZAP-70. Western blotting was 
performed on anti-ZAP-70 immunoprecipitated (IP: a-ZAP-70) samples with anti-
phosphotyrosine antibody (IB: a-PY) (Panel A). The blots were stripped and reprobed with 
monoclonal anti-ZAP-70 antibody (IB: ZAP-70) (Panel B). Treatment modalities are indicated 
below the blots. A representative Western blot is shown from 3 independent experiments with 
similar results.  
 
4.6 GR co-precipitates with ZAP-70 in the lysates of DX 
treated Jurkat cells  
Since previously we have found that sort term high dose DX treatment 
increased the phosphotyrosine content of the ZAP-70 molecule, we sought a 
possible association between the ZAP-70 and the GR molecules in Jurkat 
cells. Therefore we performed immunoprecipitation on DX or vehicle treated 
Jurkat cell lysates, both with anti-ZAP-70 and anti-GR antibodies, to 
investigate whether there is a physical link between GR and ZAP-70 in the 
cytoplasm. In GR antibody precipitated lysates we found that ZAP-70 signal 
increased significantly upon DX treatment, compared to the vehicle treated 
samples, while the GR signal was unchanged (Figure 14.). In the ZAP-70 
antibody precipitated lysates GR signal increased significantly upon DX 
treatment, when compared to vehicle treated cell lysates, while the ZAP-70 
signal remained unchanged (Figure 14.). So in DX treated Jurkat cells the GR 
co-precipitated with ZAP-70 and vica versa, while the association of the two 
molecules was minimal in the vehicle-treated control lysates (Figure 14.).  
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4.7 The ligand-bound GR co-localises with ZAP-70 in the 
cytoplasm of Jurkat cells  
To characterise the localization and relation of the ZAP-70 and GR molecules 
in the cytoplasm further, we visualised the two molecules parallel by confocal 
microscopy. In vehicle treated, resting Jurkat cells both ZAP-70 and GR 
showed even, mostly cytoplasmic distribution, with almost no co-localization. 
Upon 5 min high dose DX treatment we observed near-membrane staining of 
both the GR and ZAP-70 molecules with markedly increased co-localization of 
the two molecules (Figure 15.). Thus we confirmed our immunoprecipitation 
results with confocal microscopic pictures also. 
 
 
 
Figure 14. Co-precipitation of 
liganded GR with ZAP-70 kinase 
occurs in Jurkat cells. When anti-
GR antibody was used for 
immunoprecipitation (IP: a-GR), 
equal amount of GR precipitated 
(Blot:a-GR), but ZAP-70 co-
precipitated only when DX was 
present. (Blot: a-ZAP-70) 
Similarly, when anti-ZAP-70 was 
the precipitating antibody (IP: a-
ZAP-70) equal amount of ZAP-70 
was present both in the control 
and DX treated samples but GR 
co-precipitated with ZAP-70 only 
in the DX-treated sample. 
Figure 15. Confocal 
microscopic examination of 
GR and ZAP-70 co-
localization. Jurkat cells 
were fixed and labelled with 
a-GR-FITC (green channel) 
and a-ZAP-70-PE (red 
channel). The cells were 
sedimented on slides and 
examinated with a confocal 
microscope. In the DX-
treated samples the GR 
and the ZAP-70 showed 
near-membrane co-
localisation, while this 
phenomenon was absent in 
the untreated controls.  
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4.8 The GR co-precipitates with ZAP-70 in the DX treated 
samples of HeLa-trZAP-70 cell lysates 
As ZAP-70 is a T-and NK cell specific molecule and it is in close relation with 
other lymphocyte specific molecules e.g. the p56-lck, we wanted to investigate 
whether the co-precipitation of the GR and ZAP-70 molecules were 
dependent on lymphocyte specific factors. We used a novel lentiviral vector 
construct for transfecting ZAP-70 deficient Jurkat cells (P-116) and HeLa 
human epithelial carcinoma cells to stably express the full-length ZAP-70 
kinase. The ZAP-70 expression level in transfected P116 cells showed to be 
higher (MFI: 98) than that of Jurkat cells (MFI: 28) as tested by flow cytometry 
(Figure 16. A). The ZAP-70 construct showed to be fully functional in P116 
cells as tested by anti-CD3 activation and consequent intracellular calcium 
signal measurement using flow cytometry (Figure 16. B). Despite the higher 
ZAP-70 expression in ZAP-70 transfected P116 cells, the kinetics and 
amplitude of the calcium signal was similar to that of wild type Jurkat cells 
(Figure 16. B).  
The ZAP-70 expression level in transfected HeLa cells showed to be higher 
(MFI: 108) to that of Jurkat cells (MFI: 28) as tested by flow cytometry (Figure 
17. A). Immunoprecipitations with anti-ZAP-70 and anti-GR antibodies were 
performed from HeLa cell lysates (Figure 15. B). The ZAP-70 kinase co-
precipitated with the GR and vica versa in transgenic HeLa cells expressing 
ZAP-70 in the DX-treated samples but in the absence of its ligand the 
clustering of the two molecules was absent (Figure 17. B), similarly to what we 
have found in Jurkat cells. Co-localization of the two molecules was also 
verified with fluorescence confocal microscopy (Figure 18). We found the 
perinuclear co-localization of the transfected ZAP-70 molecule with the GR in 
ZAP-70 transfected Hela cells (Figure 18.). Upon 5 min high dose DX 
treatment we observed intensive cytoplasmic staining of both the GR and 
ZAP-70 molecules with markedly increased co-localization of the two 
molecules (Figure 18.). 
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Figure 16. Lentiviral transfection of ZAP-70 deficient P116 cells with  ZAP-70. Panel A: ZAP-
70 expression of ZAP-70 transfected P116 cells was compared to untransfected P116 and 
Jurkat cells by flow cytometry after intracellular phycoerythrine (PE) conjugated anti-ZAP-70 
antibody labelling. Flow cytometric histogram shows PE conjugated anti-ZAP-70 fluorescence 
(FL2) of a representative measurement from three separate experiments. Panel B: Calcium 
signal of ZAP-70 transfected P116 cells (▲) was compared to untransfected P116 (●) and 
Jurkat cells (■) by flow cytometry after Fluo-3 loading of samples. Anti-CD3 antibody was 
added to the cells at zero time point, then calcium level changes were followed as FL1 
fluorescence changes for 400 seconds. Curves show the result of a representative 
measurement from three separate experiments. 
 
4.9 ZAP-70 and Hsp-90 co-pecipitation in Jurkat and HeLa-
trZAP-70  lysates could be inhibited by geldanamycin 
 
Since the unliganded GR complexes Hsp-90 in the cytoplasm [124], and the 
upstream kinase p56-lck is also an Hsp-90 client protein [125], we aimed to 
check the relation of ZAP-70 to Hsp-90. We found that Hsp-90 co-precipitated 
with ZAP-70 from both Jurkat and HeLa-trZAP-70 cell lysates (Figure 19.). 
This co-precipitation was detectable both in DX and vehicle treated samples 
(Figure 19.). To further elucidate the relations of these three molecules: ZAP-
70, GR and Hsp-90 in Jurkat cells we used geldanamycin (GA) to specifically 
inhibit Hsp-90 and we performed immunoprecipitation with anti-ZAP-70 
antibody (Figure 20.). Hsp-90 failed to co-precipitate with ZAP-70 in the GA 
treated samples (Figure 20.). Although GA inhibited the co-precipitation of 
ZAP-70 with Hsp-90, it could not abrogate the DX induced GR-ZAP-70 
association. (Figure 20.) 
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Figure 17. Liganded GR clustering with ZAP-70 in ZAP-70 transfected HeLa cells. Panel A: 
Representative flow cytometric histograms show the ZAP-70 expression as FL2 fluorescence 
of control and ZAP-70 transfected HeLa cells after intracellular labelling with phycoerythrin 
(PE) conjugated anti-ZAP-70 antibody. Panel B: Anti-GR or anti-ZAP-70 Western blots are 
shown from anti-GR or anti-ZAP-70 precipitated ZAP-70 expressing HeLa cell lysates with or 
without DX pretreatment. Using anti-GR antibody for immunoprecipitation (IP: a-GR, left 
panels), equal amount of GR precipitated (Blot: a-GR, upper left panel), but ZAP-70 co-
precipitated only when DX was present (Blot: a-ZAP-70, lower left), similary as we found in 
Jurkat cells. Vica versa, when the precipitating antibody was anti-ZAP-70 (IP: a-ZAP-70, right 
panels) equal amount of ZAP-70 was present both in the control and DX treated samples 
(Blot: a ZAP-70, lower right panel) but GR co-precipitated with ZAP-70 only in the DX-treated 
sample(Blot: a-GR, upper right panel). The figure shows a representative blot from three 
separate experiments. 
 
 
Figure 18. Confocal microscopic examination of GR and ZAP-70 co-localisation in transgenic 
HeLa/ZAP-70 cells. DX treated or untreated monolayers of HeLa/ZAP-70 cells growing on a 
coverslip were fixed and subjected intracellular labelling with a-GR-FITC (green channel) and 
a-ZAP-70-PE (red channel). The coverslips were mounted on slides and examinated with a 
confocal microscope. In the DX-treated samples the GR and the ZAP-70 showed perinuclear 
co-localisation, while this phenomenon was absent in the untreated controls. 
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Figure 19. ZAP-70 co-precipitates with Hsp-90 
chaperone. We used anti-ZAP-70 as the 
precipitating antibody. (IP: a-ZAP-70) Equal 
amount of Hsp-90 co-precipitated both in the 
control and DX treated samples, suggesting 
that the ZAP-70 Hsp-90 co-clustering is 
independent of the presence or absence of 
GC hormone. The amount of precipitated ZAP-
70 was also checked and found to be equal. 
(Blot: a-ZAP-70) The co-precipitation of Hsp-
90 with ZAP-70 occurs both in Jurkat cells and 
ZAP-70 expressing HeLa cells.  
Figure 20. Geldanamycin (GA) treatment does 
not inhibit the Dexamethasone induced ZAP-70 
– GR co-precipitation. Anti-GR (upper panel), 
anti-Hsp-90 (middle panel) or anti-ZAP-70 
(lower panel) Western blots are shown from 
anti-ZAP-70 precipitated (IP: a-ZAP-70) control 
or DX treated Jurkat cell lysates with or without 
GA pretreatment. More GR co-precipitated with 
ZAP-70 in the DX-treated sample compared to 
control (Blot: a-GR, upper panel), while equal 
amount of ZAP-70 was present in both samples 
(Blot: a-ZAP-70, lower panel). GR co-
precipitation with the ZAP-70 was abrogated by 
GA in control samples, but was unaltered after 
DX treatment (Blot: a-GR, upper panel). Equal 
amount of Hsp-90 co-precipitated with ZAP-70 
both in the control and DX treated samples, 
which was completely abrogated by GA  
pretreatment (Blot: Hsp-90, middle panel). The 
amount of precipitated ZAP-70 was found to be 
equal in control and DX treated samples with or 
without GA pretreatment (Blot: a-ZAP-70, lower 
panel). The panels of the figure show 
representative blots from three separate 
experiments. 
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4.10  High dose DX treatment rapidly abrogates ZAP-70 
association with the CD3 complex in Jurkat T-cells.  
ZAP-70 plays a key role in the signal transduction pathways originating from 
the TcR-CD3 complex. T-cell activation caused by either TcR engaged by 
peptide primed MHC or cross-linking with anti-CD3 antibody triggers tyrosine 
phosphorylation events. After ZAP-70 molecules becomes phosphorylated 
(autophosphorylation and src-family kinase mediated phosphorylation) 
associate with the ITAM-tyrosines by their tandem SH2 domains. This step is 
crucial considering further activation events. Our results demonstrate that 
ZAP-70 association with the CD3 complex is abrogated in the presence of 
high dose DX, as it failed to co-precipitate in the DX treated samples. (Figure 
21.)  
 
Figure 21. DX treatment 
rapidly inhibits the 
association of ZAP-70 with 
the CD3 complex in Jurkat 
cells. CD3 complex and 
associated molecules were 
precipitated from lysates of 
anti-CD3 (OKT-3) activated 
Jurkat cells. (IP: OKT-3) The 
blots were probed (IB) with 
both anti-ZAP-70 and anti-
CD3-ξ antibodies. More ZAP-
70 is associated with the CD3 
complex in the control 
sample (ctr) than that of in 
the DX treated sample(DX) 
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5 Discussion 
 
Our work was aimed at clarifying the possible linkage between the GR and 
TcR signal transduction pathways. Jurkat cells are a widely used in vitro 
model for T-cell signalling. The immunosuppressive effect of GC has been 
known for a long time. There are data about GC induced changes of tyrosine 
phosphorylation [60]. However, GC treatment applied by the authors in that 
experimental system was considerably longer (from a few hours to overnight 
time scale), although the effects were regarded to be non-genomic. The GC 
effects we studied occurred within minutes which definitely suggest a non-
genomic way of action. We found that the rapid DX treatment induced 
phosphorylation events in Jurkat cells, while the DX pre-treatment abolished 
the phosphorylation of numerous proteins after anti-CD3 treatment. These 
results confirm the findings described by others [60], although on a completely 
different time scale.  
ZAP-70 kinase plays a central role in the signalling processes originating from 
the TcR [84]. After the TcR engages the peptide primed MHC the ITAMs 
become rapidly phosphorylated. This is mediated by src-family kinases [63]. 
The ZAP-70 docks on the phosphorylated ITAM tyrosines and it is 
phosphorylated by src-family kinases. Then ZAP-70, being activated, 
phosphorylates other signalling proteins, e.g. the LAT, SLP-76 among others. 
We examined whether DX treatment changes the phosphorylation of ZAP-70. 
Our results demonstrated that DX caused marked increase in the 
phosphotyrosine content of ZAP-70. However, DX or anti-CD3 antibody 
induced similar level ZAP-70 phosphorylation, while combined DX+anti-CD3 
treatment caused a further rise in ZAP-70 phosphotyrosine content. This 
observation suggests that anti-CD3 and DX treatment induces 
phosphorylation of different tyrosine residues on ZAP-70. Tyrosine 
phosphorylation is a common way of activity regulation in signal transduction. 
The human ZAP-70 consists of 619 amino acids and contains 30 tyrosine 
residues. Recently 11 tyrosines were identified as phosphorylation sites. 
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Some phosphorylated tyrosine residues serve as activatory or inhibitory sites, 
influencing directly the kinase activity. Others serve as docking sites for other 
regulatory proteins which exert various functions. Some phosphorylation sites’ 
function is unknown yet. (Literature data summarized in Table 2).  
Some authors describe that DX treatment inhibits the TcR induced proximal 
tyrosine phosphorylation events. Van Leathem et al. demonstrates that 6-16 
hours of 1 µM DX treatment causes decreased phosphorylation of TcR ζ 
chain, ZAP-70 and LAT [60]. The authors suggested that this is because DX 
changes the compartmentalisation of important lipid-raft associated molecules 
by altering acylation [61]. Determining the concentration of GC used in various 
experimental systems is rather difficult. In our experiments 10µM (4µg/ml) 
Dexamethasone (DX) was applied. This is a pharmacological dose, much 
higher than the physiological GC level in the human serum. GCs are often 
applied in very high doses in clinical usage, especially when rapid effects are 
needed. (E.g.: spinal cord injury: 30mg/kg body weight methylprednisolone, 
osteoarthritis: 25-40mg triamcinolone acetonide or 2-4 mg dexamethasone 
intraarticulary (knee)). Very few publications are about the rapid, non-genomic 
effects of glucocorticoids. Buttgereit et al? [39] used methylprednisolone 
hemisuccinate-Na in a concentration range of 0.1-1.0 mg per 107 cells (1-
10mM)? This concentration is one hundred-one thousand times higher than we 
used. Although the physiologic GC concentration in the serum is much lower, 
T-cells may encounter high local GC concentrations in the thymus? where local 
GC production of the thymic epithel was observed [126].  
The increased ZAP-70 phosphorylation after DX treatment opposes the 
results described by Van Leathem et al. To elucidate this controversy, we 
designed experiments to reveal the time kinetics of DX induced ZAP-70 
phosphorylation. We observed that DX caused a rapid, transient increase in 
ZAP-70 phosphorylation which declined after 5 minutes. These rapidly 
occurring phosphorylation events indicate the participation of near-membrane 
molecules. The ZAP-70 is one of the main substrates of p56-lck, which is 
constantly directed to membrane lipid rafts by N-terminal palmitoylation. Our 
finding that the DX induced ZAP-70 phosphorylation was absent in p56-lck 
deficient JCaM1.6 cells clearly suggests the involvement of p56-lck in the 
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process. Intriguingly, the ZAP-70 phosphorylation after CD3 crosslinking 
seemed to be intact in JCaM1.6 cells. This might be due to the compensatory 
effects of other src-family kinases, presumably p59-fyn, which remains active 
in JCaM1.6 cells [127]. This confirms our theory that different tyrosine 
residues become phosphorylated after anti-CD3 and DX treatment.  
Steroid hormones like GCs exert their effects via their cytoplasmic receptor, 
but presumably membrane receptors may also participate in mediating 
hormone action. Some authors propose the role of non-specific 
physicochemical effects in non-genomic steroid action. However, these effects 
were shown to occur only at extremely high steroid concentration [26]. We 
demonstrated that equimolar RU486 (Mifepristone, GR antagonist) treatment 
prevented the DX induced ZAP-70 phosphorylation. This refers to a classical 
cytoplasmic GR mediated process. The inactive GR associates with Hsp-90 in 
the cytoplasm. Others described the linkage of p56-lck and Hsp-90 [125]. 
Additionally, the Hsp-90 apparently plays an important role in maintaining the 
active conformation of p56-lck. The disruption of functional Hsp-90 with 
geldanamycin inhibits p56-lck kinase activity and consequently impairs TcR 
signalling [125]. So it raised the possibility that GR, ZAP-70 and Hsp-90 are 
closely related in the cytoplasm being parts of the macromolecular complex 
organised by Hsp-90. This theory is supported by our results that GR co-
precipitates with the ZAP-70 and vica versa in Jurkat cells and in transgenic 
HeLa cells. This suggests the direct physical association of the two molecules, 
which is independent of p56-lck since this molecule is not expressed in HeLa 
cells. The fact that GR agonist promoted the clustering of ZAP-70 and GR 
might suggests that the transmission of the signal presumably occur via direct 
physical association of the two molecules. We also confirmed the close 
relation of these two molecules upon DX treatment in the near membrane 
compartment of the cytoplasm of Jurkat cells by confocal microscopy. We 
found minimal association between ZAP-70 and the GR in untreated cells. 
Both experimental approaches showed that the presence of GR ligand 
facilitated the GR association with the ZAP-70 kinase. It is interesting to 
observe that co-localization of GR and ZAP-70 occurred both in Jurkat and in 
HeLa-trZAP-70 cells, although showing different pattern. The co-clustering of 
ZAP-70 and GR in Jurkat cells occurred in the near-membrane compartment, 
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while that of in HeLa-trZAP-70 cells showed perinuclear co-localization 
pattern. Presumably in Jurkat cells, where the TcR-associated signaling 
machinery is complete, ZAP-70 is directed towards the membrane during the 
signal transduction processes. In HeLa cells, where the transgenic expressed 
ZAP-70 is somewhat incompatible, the partner molecules determining 
membrane orientation are absent resulting in different co-localization pattern. 
Interestingly, our results show that ZAP-70 also co-precipitated with the Hsp-
90 chaperone. Other authors also describe the co-clustering of ZAP-70 and 
Hsp-90 in B-CLL cells isolated from the blood of leukaemic patients [128]. 
Although ZAP-70 is a T- and NK-cell specific molecule, it is pathologically 
expressed by malignant B-CLL cells, where it is associated to the activated 
form of Hsp-90, while the authors found no such phenomenon in healthy T-
cells. Castro and colleagues proposed that the B-CLL cells, similarly to many 
other tumor cells, express the “activated” form of Hsp-90, with high ATPase 
activity [128], existing in multi-chaperone complexes [129], whereas normal 
cells express Hsp-90 in its non-activated form, which does not associate with 
ZAP-70 [128]. Our results show that the association of ZAP-70 with the Hsp-
90 was independent from the presence or absence of the GR agonist, but it 
could be abrogated with the Hsp-90 antagonist geldanamycin. As Jurkat cells 
themselves are of malignant origin, the ZAP-70-Hsp-90 association might 
represent a new aspect of the leukaemic phenotype. It is accepted that the 
GR dissociates the Hsp-90 after ligand binding [16]. Here we describe the 
ligand dependent association of the GR to ZAP-70, which cannot be blocked 
by geldanamycin. Based on these data we conclude that Hsp-90 complexes a 
lot of client proteins in the cytoplasm, both ligand-free GR and ZAP-70 among 
others. When GR ligand is present the ZAP-70-GR association increases and 
becomes Hsp-90 independent. We hypothesize that the ZAP-70 might exist in 
two forms in the cytoplasm of Jurkat cells, whether or not it is associated to 
the chaperone Hsp-90. There seems to be a relatively constant amount of 
ZAP-70 bound to Hsp-90, which is not affected by GR agonist treatment and 
therefore possibly is not involved in the rapid GR induced phosphorylation 
events. On the other hand, the non-Hsp-90 bound ZAP-70 fraction would 
associate with the ligand-bound GR and consequently might be involved in 
the cross talk between the TcR and GR signaling pathways. If we take into 
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consideration the findings of Castro and colleagues [128], we might speculate 
the “activated” Hsp-90 associated ZAP-70 fraction might represent an inactive 
molecular fraction in the cytoplasm of leukaemic Jurkat cells.  
The fact that DX treatment inhibited the ZAP-70 kinase association with the 
CD3 complex in activated cells, raises the possibility that this non-genomic 
GC effect described here takes part in the well-known GC mechanism of 
suppressing T-cell activation and function. According to our recent knowledge 
in cellular signaling, the exact temporospatial organization of the participating 
molecules is of key importance in the proper signaling function. We found 
along with others [130], that DX treatment disrupts the CD3-associated 
signaling complex preventing ZAP-70 from the association with the TcR-CD3 
complex. If the association of ZAP-70 with the CD3 chains is inhibited, the T-
cell activation is at least defective or can lead to anergy.  
In conclusion, our experiments described here suggest the existence of a 
previously unrevealed function of the ZAP-70: a junction between the GR and 
TcR signal transduction pathway that might also be affected by the chaperone 
Hsp-90. However, the exact role of ZAP-70, p56-lck and Hsp-90 at the 
molecular level needs further elucidation. We plan further examination of the 
GC mediated effects on signal transduction processes downstream of ZAP-
70.   
 
 
 
Figure 21.  
Our concept on TcR-CD3- and 
GR signal transduction crosstalk 
mechanisms. We suggest that 
GC hormone causes multiple 
tyrosine phosphorylation 
changes as we demonstrated on 
Jurkat cell lysates and 
precipitated ZAP-70 samples. 
The GC hormone caused rapid 
phosphorylation changes of the 
ZAP-70 kinase. After ligand 
binding, the GR associates with 
the ZAP-70 kinase and ZAP-70 
recruitment to the CD3 complex 
is inhibited. We assume that 
these processes might be partly 
responsible for the inhibitory 
effect of the GC hormone on T-
cell activation.  
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Abstract
Steroid hormones are known to mediate rapid non-genomic effects occurring within minutes, besides the classical genomic actions mediated
by the nuclear translocation of the cytoplasmic glucocorticoid receptor (GR). The glucocorticoid hormone (GC) has significant role in the
regulation of T-cell activation; however, the cross-talk between the GC and T-cell receptor (TcR) signal transducing pathways are still to
be elucidated. We examined the rapid effects of GC exposure on in vitro cultured human T-cells. Our results showed that Dexamethasone
(
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dDX), a GC analogue, when applied at high dose (10M), induced rapid (within 5 min) tyrosine-phosphorylation events in Jurkat cells. Short
X pre-treatment strongly inhibited the tyrosine-phosphorylation stimulated by CD3 cross-linking. Furthermore, we also investigated the
hosphorylation status of ZAP-70, an important member of tyrosine kinase mediated signalling pathway of TcR-elicited T-cell activation. Here,
e demonstrate that high dose DX induced a rapid ZAP-70 tyrosine-phosphorylation in Jurkat T-cells. DX-induced ZAP-70 phosphorylation
ould be inhibited by RU486 (GR antagonist), suggesting that this process was GR mediated. DX-induced ZAP-70 phosphorylation did not
ccur in the absence of active p56-lck as examined in the p56-lck kinase-deficient Jurkat cell line JCaM1.6. Our results show that DX, at a
igh dose, can rapidly influence the initial tyrosine-phosphorylation events of the CD3 signalling pathway in Jurkat cells, thereby modifying
cR-derived signals. Lck and ZAP-70 represent an important molecular link between the TcR and GC signalling pathways.
2005 Elsevier Ltd. All rights reserved.
eywords: Glucocorticoid hormone; Glucocorticoid hormone receptor; Non-genomic effects; ZAP-70; Tyrosine-phosphorylation; Jurkat cells
. Introduction
Glucocorticoid hormones (GCs) participate in the regula-
ion of differentiation, activation, survival and apoptosis of
lymphocytes [1]. GCs modulate the immune response by
nhibiting the cellular (Th1) branch of the immune response
hile promoting humoral (Th2) response [2]. For these rea-
ons GCs have been used as immunosuppressive therapeutic
gents for 50 years in autoimmune and other inflammatory
iseases, organ transplantations and haematological malig-
ancies [2,3].
The major physiological source of GCs is the adrenal
lands [4], but extraadrenal GC production was also found
n the thymus [5], the chicken bursa [6] and the intestinal
∗ Corresponding author. Tel.: +36 72 536 288; fax: +36 72 536 289.
E-mail address: dominicus@freemail.hu (D. Bartis).
epithelial cells [7]. Depending on other simultaneous sig-
nalling processes, extraadrenally produced GCs can posses
local immunomodulatory effects, eliciting both stimulatory
and inhibitory responses [7,8].
In addition to a number of other GC-sensitive tissues like
lung, spleen, brain, liver, kidney, heart, adrenal, testis [11],
muscle, different cell lines and tumors [12], mature peripheral
T-cells [9] and thymocytes [10] also express glucocorticoid
receptor (GR). The inactive form of GR is associated with
Hsp-90 in the cytoplasm [13]. Upon ligand binding, GR dis-
sociates from Hsp-90 and translocates to the nucleus, where
it forms dimers and functions as transcription factor, binding
to specific conserved palindromic DNA sequences (GGTA-
CAnnnTGTTCT), called glucocorticoid response elements
(GRE) [14]. The receptor translocation to the nucleus occurs
within 30 min in HepG2 cell line [15], and subsequent gene
transcription effects develop within hours.
960-0760/$ – see front matter © 2005 Elsevier Ltd. All rights reserved.
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Accumulating evidence show that besides the classi-
cal genomic GC action, other, non-genomic mechanisms
also exist. The recent opinion is that rapid GC effects
might be mediated through three different mechanisms: (1)
specific cytoplasmic protein–protein interactions involving
the cytoplasmic GR (cGR), (2) specific signalling mecha-
nisms through the membrane-bound GR and (3) non-specific
physico-chemical GC interactions with the cell membrane
[16]. Croxtall et al. observed that epidermal growth fac-
tor (EGF)-stimulated cPLA2 (cytosolic PLA2) activation
with subsequent arachidonic acid release could be inhibited
by Dexamethasone [17]. This effect was considered to be
a glucocorticoid receptor-dependent (RU486-sensitive), but
transcription-independent (actinomycin-insensitive) mecha-
nism [17]. Hitherto all steroid hormone classes (glucocor-
ticoids, progesterone, estrogens, androgens, neurosteroids,
mineralocorticoids, Vitamins D3, T3 and T4) have been
shown to mediate rapid, non-genomic effects [18]; however,
the exact signalling mechanisms are still to be identified.
It has been shown that GCs inhibit the early steps of
TcR signalling events such as the calcium flux, inosi-
tol phosphate production and phospholipase-C1 tyrosine-
phosphorylation following TcR ligation in murine T-cell
hybrids [19]. GCs also inhibit the phosphorylation of some
early T-cell signalling molecules such as the T-cell receptor
(TcR) zeta chain and the ZAP-70 kinase in T-cell hybridomas
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2. Materials and methods
2.1. Cell lines
We used Jurkat cells (human acute T-cell leukemia) and
its p56-lck-deficient subclone (JCaM1.6), both a generous
gift from E. Monostori (Biological Research Centre, Szeged,
Hungary). Cells were cultured in humidified atmosphere,
containing 5% CO2 at 37 ◦C, in RPMI medium supplemented
with 5 and 10% fetal calf serum (Gibco, Gaithersburg, MD,
USA), respectively.
2.2. Chemicals and buffers
All fine chemicals were purchased from Sigma–Aldrich
(St. Louis, MO, USA) otherwise indicated. Dexamethasone
was used as glucocorticoid hormone agonist and RU486
(Mifepristone) was used as glucocorticoid antagonist, both
dissolved in DMSO at a concentration of 10 mM. For the
Western blot experiments Jurkat cells were lysed in ice-
cold lysis buffer (50 mM HEPES, 10 mM sodium pyrophos-
phate 10 mM EDTA, 100 mM sodium fluoride, 10% glycerol
and 1% Triton X-100). Aprotinin, leupeptin (Fluka, Buchs,
Switzerland) (10g/ml), PMSF (2 mM) and sodium ortho-
vanadate (2 mM) were freshly added to the lysis buffer.
The cell lysates were separated by SDS-PAGE after adding
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bnd murine thymocytes [20]. The authors proposed a non-
enomic GC signalling mechanism through the cytoplasmic
R which affected the membrane compartmentalisation of
rc-family kinases [20]. They also found that GC hormone
reatment altered the lipid composition of lipid rafts of a
urine T-cell hybridoma, thereby altering the raft association
nd palmitoylation of key signalling molecules [21]. How-
ver, the GC effects described in the above works [19–21]
eeded hours to manifest. Only few data are available about
he signalling mechanisms induced by rapid steroid effects
hich occur within minutes. Particularly, the modulatory
ffects of steroid hormones on the phosphorylation status of
ey signalling elements are sparse, therefore we set out to
nvestigate this process in more depth.
It has been shown that the Vitamin D receptor mediates
apid src tyrosine-phosphorylation and consequent MAP-
inase activation in muscle cells following ligand binding
22,23]. Boonyaratanakornkit et al. found that the proges-
erone receptor interacts with the src-family tyrosine kinases
ia their SH3 domains and stimulates the activation of the
as/Raf-1/MAP-kinase pathway [24].
In this paper, we report that Dexamethasone (DX), a gluco-
orticoid hormone analogue, rapidly diminishes the tyrosine-
hosphorylation events caused by CD3 cross-linking. We
ssayed the phosphorylation status of ZAP-70, a key T-
ell signalling protein and found that high dose DX rapidly
nduced its phosphorylation on tyrosine residues. The DX-
nduced phosphorylation process proved to be sensitive to the
R antagonist RU486 and was absent in p56-lck-deficient
urkat cells.qual amount of 2× sample buffer (125 mM Tris, 4% SDS,
0% glycerol, 0.006% Bromo-phenol-blue and 10% mer-
aptoethanol) or subjected to immunoprecipitation. The gels
ere blotted overnight to nitrocellulose membranes using
Trans-Blot cell blotting equipment (both from Bio-Rad,
ercules, CA, USA). To saturate non-specific binding sites,
he blots were soaked in blocking buffer (1% bovine serum
lbumin, 10 mM Tris, 100 mM sodium chloride and 0.1%
ween 20, pH 7.4) For washing the blots washing buffer
as used (10 mM Tris, 100 mM sodium chloride and 0.1%
ween-20, pH 7.4). Western blot visualisation was performed
y enhanced chemiluminescence as described in the manu-
acturer’s instructions (SuperSignal West Pico Chemilumi-
escent substrate (Pierce, Rockford, IL, USA) or, in case
f anti-ZAP-70 immunoblots with bromo-chloro-indolyl-
hosphate/nitro-blue tetrazolium (BCIP/NBT), in a 100 mM
odium chloride, 50 mM Tris, 5 mM MgCl2, pH 9.5, buffer.
or stripping the blots we used Restore Stripping Buffer
Pierce).
.3. Antibodies
We used mouse monoclonal anti-human CD3 antibody
clone: UCHT-1, 1 mg/ml stock solution in PBS) for cell
ctivation. Immunoprecipitation was performed with puri-
ed rabbit polyclonal anti-ZAP-70 antibody (kindly provided
y E. Monostori, Biological Research Centre, Szeged, Hun-
ary). The tyrosine-phosphorylation pattern was examined
y using biotinylated monoclonal anti-phosphotyrosine anti-
ody (clone: PY20, Transduction Laboratories, Lexington,
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KY, USA) and HRPO-conjugated streptavidin (Amersham,
Little Chalfont, UK) as a secondary reagent. To prove the
equal protein loading we used monoclonal mouse anti--
actin antibody (Sigma). ZAP-70 immunoblots were probed
with monoclonal anti-ZAP-70 antibody (clone: 29, Trans-
duction Laboratories) and alkaline-phosphatase labelled rab-
bit polyclonal anti-mouse (DakoCytomation, Glostrup, Den-
mark) secondary antibody. Biotinylated monoclonal anti-
insulin antibody (clone: 2D11) was used as negative control.
2.4. Glucocorticoid analogue and glucocorticoid
antagonist treatment
Jurkat cells were cultured for 4 h in RPMI supplemented
with 10−5 M RU486 or solvent. After the exposure, cells were
harvested, and 5 × 106 to 107 cells per sample were resus-
pended in 500l RPMI. 10−5 M Dexamethasone was added
and cells were incubated at 37 ◦C for various periods as indi-
cated.
2.5. Cell activation and lysis
Fifty micrograms UCHT-1 anti-CD3 monoclonal anti-
body was added to the DX-treated or untreated samples.
Following 1 or 2 min of incubation at 37 ◦C the activation
was stopped by quickly freezing the cells in liquid nitrogen.
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body. Following extensive washing the alkaline-phosphatase
labelled rabbit anti-mouse antibody (1:2000 dilution) was
added for another 1 h. Reprobed Western blots were visu-
alised with BCIP/NBT substrate.
2.7. Analysis of blots
Densitometry of the blots was carried out with the
ScionImage software (Scion Corporation, Frederick, MD,
USA). Relative densities of phosphotyrosine blots were cor-
rected with relative densities of ZAP-70 blots of the same
sample, to obtain the relative phosphorylation levels of ZAP-
70 in each sample.
2.8. Statistical analysis
Each experiment was repeated three times and represen-
tative blots are shown in the figures. The effect of treatments
was tested for statistical significance using Student’s t-test.
P < 0.05 denoted statistical significance.
3. Results
3.1. Dexamethasone alters the tyrosine-phosphorylation
pattern of Jurkat cells
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ihen, the samples were lysed for 30 min in 500l ice-cold
ysis buffer. Following lysis the samples were centrifuged
t 13,000 rpm for 15 min at 4 ◦C. Postnuclear supernatants
ere aspirated and boiled for 5 min with equal amounts of
× sample buffer or subjected to immunoprecipitation.
.6. Immunoprecipitation and Western blot
Equal amounts of cell lysates were incubated on a rotator
latform at 4 ◦C for 2 h with 10l of the precipitating anti-
erum. Then, 30l slurry of Protein G coupled Sepharose
eads were added for additional 2 h. The beads were pelleted
nd five washes were performed with ice-cold washing buffer.
fter washing the beads were resuspended in 100l of SDS
ample buffer and the immunoprecipitates were boiled for
min. After a quick spin the supernatants were collected and
oaded on 7.5 or 10% SDS-polyacrylamide gels. SDS-PAGE
as performed using a BioRad MiniProtean elecrophoresis
quipment. The gels were blotted overnight to nitrocellulose
embranes by wet transfer procedure. After blocking non-
pecific binding sites for 1 h, the blots were incubated for
h with 0.2g biotinylated monoclonal anti-PY antibody.
estern blot negative controls were incubated with biotiny-
ated monoclonal anti-insulin antibody for the same time
eriod at the same concentration. Following extensive wash-
ng, the HRPO-conjugated streptavidin (1:5000 dilution)
as added for another hour. Western blots were visualised
ith SuperSignal West Pico Chemiluminescent substrate.
hen stripping of the membranes was performed and blots
ere reprobed with 0.5g of monoclonal anti-ZAP-70 anti-First we examined how DX treatment influences the
yrosine-phosphorylation pattern of resting and anti-CD3
ctivated Jurkat cells. Two minutes of 10M DX treatment
lone caused increased protein tyrosine-phosphorylation at
he 34, 52, 59, 70 and 90 kDa molecular weight bands in
hole Jurkat cell lysates, compared to the solvent-treated
ontrol (Fig. 1). Activation with monoclonal anti-CD3 anti-
ody markedly increased the tyrosine-phosphorylation of
everal proteins in whole cell lysates at 25, 34, 38, 40, 52, 59,
0 and 90 kDa molecular weight ranges, respectively (Fig. 1).
2 min DX pre-treatment at 10M concentration inhibited
he anti-CD3-induced tyrosine-phosphorylation the proteins
f 34, 38, 40, 52, 59 and 90 kDa (Fig. 1). We got no significant
ignal on negative control blots, incubated with biotinylated
onoclonal anti-insulin antibody (data not shown).
.2. High dose Dexamethasone rapidly induces ZAP-70
hosphorylation
ZAP-70 plays a central role in the TcR signal transduction
athway, by phosphorylating a broad range of substrates, and
tself is also phosphorylated on several tyrosine residues [25].
or this reason, we investigated the tyrosine-phosphorylation
f ZAP-70 after DX and/or anti-CD3 treatments. Five-minute
xposure to 10M DX caused an average of four-fold
3.32 ± 1.72) increase in tyrosine-phosphorylation of the
AP-70 kinase in the anti-ZAP-70 precipitated samples
Fig. 2). The anti-CD3 treatment also resulted in a four-fold
ncrease (3.59 ± 1.69) in the tyrosine-phosphorylation of
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Fig. 1. Dexamethasone and/or anti-CD3 treatment influenced the tyrosine-
phosphorylation pattern in Jurkat cell lysates. Western blotting was per-
formed with monoclonal anti-phosphotyrosine antibody (Panel A). Then,
the blot was stripped and reprobed with monoclonal anti-beta actin anti-
body to check equal protein loading (Panel B). Molecular weight markers
are indicated on the left, treatment modalities on the bottom side of the
blot. The experiment was repeated three times with similar results. Here, a
representative Western blot is depicted.
ZAP-70 kinase (Fig. 2). The tyrosine-phosphorylation after
combined DX + anti-CD3 treatment was higher (4.98 ± 2.83)
than in case of anti-CD3 or DX treatment alone (five-fold
versus four-fold increase, respectively). Phosphorylation
increase after single DX or anti-CD3 or combined treatments
proved significant compared to the solvent-treated control
sample (Student’s t-test, P < 0.05). We observed higher
phosphorylation after combined DX + anti-CD3 treatment
than single DX or anti-CD3 treatment in all of our indepen-
dent experiments, but this further rise was statistically not
significant by Student’s t-test (Fig. 2).
3.3. Temporal kinetics of ZAP-70
tyrosine-phosphorylation following single high dose
Dexamethasone treatment
Since the kinetics of tyrosine-phosphorylation is a key fea-
ture to understand cellular signalling events [26], we further
investigated the time course of DX-induced ZAP-70 tyrosine-
phosphorylation. The tyrosine-phosphorylation of ZAP-70
occurs rapidly after the addition of high dose DX. We mea-
sured a rise in tyrosine-phosphorylation after 1 and 2 min after
DX administration, respectively (Fig. 3). Dephosphorylation
occurred within 5 min (Fig. 3).
Fig. 2. Effect of Dexamethasone and/or anti-CD3 treatment on ZAP-70
tyrosine-phosphorylation. Western blotting was performed on anti-ZAP-
70 immunoprecipitated (IP: a-ZAP-70) samples with anti-phosphotyrosine
antibody (IB: a-PY) (Panel A). The blots were stripped and reprobed
with monoclonal anti-ZAP-70 antibody (IB: a-ZAP-70) (Panel B). The
relative phosphotyrosine content of ZAP-70 is shown as relative density
averages ± S.D. from the densitometry data of three separate experiments
(*P < 0.05) (Panel C). Treatment modalities are indicated below the diagram
(Panel C).
3.4. ZAP-70 phosphorylation induced by
Dexamethasone is p56-lck dependent
In addition to acting as a tyrosine kinase, ZAP-70 is a sub-
strate of p56-lck, a T-cell specific src-family tyrosine kinase
[27]. We therefore tested whether the DX-induced rapid
tyrosine-phosphorylation of ZAP-70 was p56-lck dependent.
When JCaM1.6, the p56-lck-deficient subclone of Jurkat cells
was subjected to high dose DX treatment, we observed no
rise in the degree of tyrosine-phosphorylation of ZAP-70
kinase (Fig. 4). The anti-CD3 activation induced notable
increase in tyrosine-phosphorylation of ZAP-70 in JCaM1.6
cells (Fig. 4). Additional DX stimulation did not alter the
Fig. 3. Time-dependent tyrosine-phosphorylation of ZAP-70 after high dose
Dexamethasone treatment. Western blotting was performed on anti-ZAP-
70 immunoprecipitated (IP: a-ZAP-70) samples with anti-phosphotyrosine
antibody (IB: a-PY) (Panel A). The blots were stripped and reprobed with
m
D
ronoclonal anti-ZAP-70 antibody (IB: ZAP-70) (Panel B). Duration of the
examethasone treatment is indicated below the figure. The experiment was
epeated three times with similar results.
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Fig. 4. ZAP-70 tyrosine-phosphorylation after Dexamethasone and/or anti-
CD3 treatment in p56-lck kinase-deficient Jurkat subclone JCaM1.6. West-
ern blotting was performed on anti-ZAP-70 immunoprecipitated (IP: a-ZAP-
70) samples with anti-phosphotyrosine antibody (IB: a-PY) (Panel A). The
blots were stripped and reprobed with monoclonal anti-ZAP-70 antibody
(IB: ZAP-70) (Panel B). Treatment modalities are indicated below the blots.
A representative Western blot is shown from three independent experiments
with similar results.
Fig. 5. Effect of RU486 (Mifepristone, glucocorticoid receptor antagonist)
pre-treatment on the Dexamethasone-induced tyrosine-phosphorylation of
ZAP-70. Western blotting was performed on anti-ZAP-70 immunoprecipi-
tated (IP: a-ZAP-70) samples with anti-phosphotyrosine antibody (IB: a-PY)
(Panel A). The blots were stripped and reprobed with monoclonal anti-ZAP-
70 antibody (IB: ZAP-70) (Panel B). Treatment modalities are indicated
below the blots. A representative Western blot is shown from three indepen-
dent experiments with similar results.
phosphotyrosine increase caused by anti-CD3 activation in
the p56-lck-deficient cell line (Fig. 4).
3.5. ZAP-70 phosphorylation can be elicited by the
glucocorticoid receptor
Previous studies indicated the existence of various non-
genomic GC effects, either GR mediated or receptor
independent. Therefore, we investigated whether tyrosine-
phosphorylation alterations in Jurkat T-cells induced by DX
were GR-dependent using RU 486 (Mifepristone), a gluco-
corticoid receptor antagonist [28]. DX alone caused markedly
growth in the tyrosine-phosphorylation of ZAP-70 (Fig. 5).
Pre-treatment of Jurkat cells for 4 h with equimolar RU486
prevented this rapid phosphorylation of ZAP-70 induced by
subsequent high dose DX exposure (Fig. 5). RU 486 treat-
ment alone caused no remarkable tyrosine-phosphorylation
change in ZAP-70 (Fig. 5).
4. Discussion
Our work was aimed at clarifying the GC-TcR signal
cross-talk in Jurkat cells in vitro. It has been known for a long
time that GCs exhibit immunosuppressive effects [2]. As a
model for TcR engagement, the cross-linking of the CD3
signalling complex with anti-CD3 antibody increases the
phosphotyrosine content in T-cells [29]. Others have shown
that GC alters the tyrosine-phosphorylation after TcR activa-
tion in T-cells [20]. However, those DX effects needed hours
to manifest, although they proved to be non-genomic. The
GC effects we demonstrate here occurred within 5 min, which
strongly suggest that these responses were non-genomic in
nature. The phosphotyrosine content of DX-treated Jurkat
cells increased, while the addition of DX reduced the degree
of tyrosine-phosphorylation in anti-CD3 activated Jurkat
cells. This demonstrated the rapid suppressive effects of GCs
on T-cell activation, which is supported by previous findings
[20], however on a considerably different time scale.
The ZAP-70 kinase has a central role in TcR signalling
[25]. After the MHC–peptide complex engaged the TcR,
the ITAMs on the CD3 complex are rapidly phosphory-
lated [25]. These phosphorylation events are mediated by
the src-family kinases [27]. Following CD3 phosphorylation,
ZAP-70 kinase is recruited to the phosphotyrosines by its
tandem SH2 domains and additional phosphorylation events
occur [26]. The ZAP-70 kinase phosphorylates LAT and other
adaptor proteins, which leads to the augmentation of the cell
activation signal [30]. We investigated whether the GC hor-
mone was able to influence ZAP-70 phosphorylation. Our
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mxperiments showed that DX caused a marked rise in ZAP-
0 tyrosine-phosphorylation within 5 min. ZAP-70 kinase
ctivity is regulated by site-specific tyrosine-phosphorylation
31,32]. Increase in the phosphotyrosine content of ZAP-
0 might lead to either the increase or inhibition of kinase
ctivity [32]. ZAP-70 is a member of the Syk-family tyro-
ine kinases, which contains 30 tyrosine residues. Several of
hese are potential phosphorylation sites. The known activa-
ion sites are Y315, Y319 [33], Y493 [34], some of them
ave inhibitory function Y292 [35], Y492 [34], others have
nknown function (Y69, Y126 and Y178), respectively [31].
Some authors previously showed that the application of
X abrogated the early events of TcR-CD3 signalling. Van
aethem et al. demonstrated that 1M DX treatment for
–16 h inhibited the phosphorylation of the TcR-zeta chain,
AP-70, and the transmembrane adaptor LAT [20]. The
uthors suggested that these effects were due to altered acy-
ation and lipid raft compartmentalisation of key signalling
olecules [21]. In our experiments, we used high dose DX
10M) for 0.5–30 min, which was considerably shorter than
eported in other experimental systems. The increased ZAP-
0 tyrosine-phosphorylation after DX treatment seemed in
ontrast to what Van Laethem et al. have found on DX atten-
ated ZAP-70 tyrosine-phosphorylation [20]. To elucidate
his controversy, we analysed the kinetics of ZAP-70 phos-
horylation response induced by DX. We found that 10M
X induced rapid, transient ZAP-70 phosphorylation, within
min and dephosphorylation occurred already after 5 min.
uch rapid GC actions suggested the involvement of near-
embrane structures. Structural data indicate that ZAP-70 is
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localised adjacent to the cytoplasmic membrane both in its
active and inactive form [36,37]. ZAP-70 is a key substrate
of src-family kinases, which also localise in lipid rafts of the
lymphocyte membranes [38], which supports this interpreta-
tion.
Next, we determined whether the DX-induced tyrosine-
phosphorylation of ZAP-70 occurred in the absence of active
p56-lck, a key kinase in T-cell activation with ZAP-70 as one
of its important substrates. Our results revealed that DX was
unable to induce ZAP-70 phosphorylation in the absence of
p56-lck, suggesting that phosphorylation events initiated by
DX in T-cells involve the p56-lck kinase. Interestingly, the
anti-CD3-induced phosphorylation of ZAP-70 in JCaM1.6
cells was not defective. This might be due to the compen-
satory effect of other src-family kinases for example p59-fyn
which might remain active in JCaM1.6 cells and participate
in ZAP-70 phosphorylation [39–41]. DX treatment could
not increase anti-CD3-induced tyrosine-phosphorylation of
ZAP-70 in the p56-lck-deficient cell line, in contrast to wild-
type Jurkat cells. This suggests that anti-CD3 activation and
DX treatment may have caused the phosphorylation of dif-
ferent tyrosine residues of ZAP-70.
Steroid hormones mediate their rapid non-genomic effects
either through the classical cytoplasmic receptor by spe-
cific protein–protein interactions or through their putative
membrane receptor. Moreover, direct physico-chemical inter-
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Gametchu demonstrated the presence of GR-like antigens
in the plasma membrane of a mouse T-lymphoma cell line
[45] and in human leukaemia cells [46], suggesting that the
GR may reside in the plasma membrane, too. The presence
of membrane GR has been shown in the membrane of normal
mononuclear blood cells [47]. Others have partially purified
and characterised a novel membrane resident GC binding pro-
tein from amphibian brain [48]. This novel mGR protein is
different from the classical cGR, since it resembles the prop-
erties of receptors containing seven transmembrane domains
[48]. Similarly, Wong et al. recently identified and cloned a
novel protein termed Modulator of Nongenomic Activity of
ER (MNAR), a previously uncharacterised scaffold protein
that modulates ER interaction with src-family protein tyro-
sine kinases [49]. They showed that this interaction leads to
src activation and the stimulation of MAPK pathway. These
data, together with our findings, raise the possibility of the
mGR participating in the mediation of rapid glucocorticoid
actions.
In conclusion, we established that the hierarchy of p56-
lck and ZAP-70 represents an important link between the GC
and TcR signalling pathways in Jurkat cells. Our data may
provide a better insight to the molecular events underlying
the rapid effects of high dose GC treatment.
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Rctions may also participate in hormone action [16]. Some
tudies showed the rapid suppressive effect of GCs on mito-
en activated human peripheral blood mononuclear cells
PBMC) [42] and rat thymocytes [43]. They showed that the
xygen consumption of the ConA-activated PBMC [42] or
at thymocytes [43] rapidly decreased in response to high
ose methylprednisolone. The administration of high dose
C diminished the sodium and calcium ion transport across
he plasma membrane and also inhibited the calcium signal
ollowing the ConA-activation in rat thymocytes [43]. These
ffects were thought to be due to direct physicochemical inter-
ctions with the plasma membrane and occurred at very high
C concentrations (1–10 mM) [43].
Our results showed that GC action was inhibited by the
pplication of equimolar Mifepristone, a GR antagonist, sug-
esting that the rapid phosphorylation events induced by DX
as mediated by the GR. The participation of GR in the rapid
teroid signalling process of Jurkat cells raises the question
hether the receptor is membrane-bound (mGR) or localises
n the cytoplasm (cGR). Hsp-90 provides a binding site for
he inactive form of cGR, which complex is dissociated by the
igand binding to GR [13]. The src-family member p56-lck
lso binds Hsp-90, which might have an important func-
ion in arranging the active conformation of the src-family
inases [44]. Moreover, the disruption of functional Hsp-90
ith geldanamycin inhibits T-cell activation and decreases
he phosphorylation of lck and Raf-1 kinases [44]. These
ata imply that the cGR and the p56-lck might localise in the
ame multimolecular compartment organised by the Hsp-90,
hereby influencing each other’s function.cknowledgements
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The glucocorticoid receptor (GR) participates in both genomic and non-genomic glucocorticoid hormone (GC) actions by interacting
with other cytoplasmic signalling proteins. Previously, we have shown that high dose Dexamethasone (DX) treatment of Jurkat cells
causes tyrosine phosphorylation of ZAP-70 within 5 min in a GR-dependent manner. By using co-immunoprecipitation and confocal
microscopy, here we demonstrate that the liganded GR physically associates with ZAP-70, in addition to its phosphorylation changes.
The association of the ligand-bound GR and ZAP-70 was also observed in HeLa cells transfected with ZAP-70, suggesting that this
co-clustering is independent of lymphocyte speciﬁc factors. Furthermore, the ZAP-70 was found to also co-precipitate with Hsp-90 chap-
erone both in Jurkat and transgenic HeLa cells, independent of the presence of DX. These ﬁndings raise the possibility that ZAP-70 may
serve as an important link between GC and TcR-induced signaling, thereby transmitting non-genomic GC action in T-cells.
 2007 Elsevier Inc. All rights reserved.
Keywords: ZAP-70; Glucocorticoid receptor (GR); Hsp-90; Non-genomic glucocorticoid eﬀects; Jurkat cellsGlucocorticoid hormones (GCs) are lipophilic steroid
molecules that can freely diﬀuse through biological mem-
branes [1]. The ligand-free glucocorticoid receptor (GR)
is a component of a multimeric protein complex in the
cytoplasm. This multi-protein complex consists of heat-
shock proteins, several immunophillins, and the inactive
GR [2]. Upon ligand binding, the GR dissociates from this
multi-protein complex, dimerises and translocates into the
nucleus, where it serves as transcription factor [3]. In the
nucleus the GR binds to speciﬁc DNA sequences called
glucocorticoid response elements (GRE) [4]. This signalling
mechanism of the GCs is called the classical, genomic path-
way. The activated GR also interacts with a number of
other transcription factors e.g., STATs, AP-1, NFjB,
and octamer transcription factors [5].0006-291X/$ - see front matter  2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2006.12.211
* Corresponding author. Fax: +36 72 536 289.
E-mail address: dominicus@freemail.hu (D. Bartis).GC eﬀects exerted through the genomic pathway result
in changes in the gene expression pattern and they need
de novo protein synthesis to occur [5]. Nevertheless, there
are GC eﬀects that cannot be explained on the basis of
the above, genomic pathway. In the clinical practice, GCs
are used in the treatment of neurotraumatic cases, such
as acute spinal cord injury [6] and acute allergic diseases
e.g., anaphylactic reactions [7,8], where rapid actions are
required. Due to the lack of time for gene expression
changes, these prompt GC eﬀects are considered to be
non-genomic eﬀects.
It has been shown that the early steps of TcR-signalling
events are inhibited by GC exposure [9]. GCs also inhibit
the phosphorylation of proximal T-cell signalling mole-
cules in T-cell hybridomas and murine thymocytes [10].
GC hormone treatment altered the lipid composition of
membrane lipid rafts of a murine T-cell hybridoma, there-
by altering the raft association and palmitoylation of key
signalling molecules [11]. However, the GC eﬀects needed
254 D. Bartis et al. / Biochemical and Biophysical Research Communications 354 (2007) 253–258hours to develop in the above works and only few data
were available until recently about the signalling mecha-
nisms induced by rapid steroid eﬀects which occur within
minutes.
Protein–protein interactions are a possible way to exert
non-genomic GC functions as proposed in the model by
Buttgereit and colleagues [12]. Some protein–protein inter-
actions are already known concerning the GR. The unli-
ganded GR is complexed with Hsp-90 chaperone in the
cytoplasm [2]. The translocation of the liganded GR dimers
into the nucleus is supported by cytoskeletal elements [13].
The Hsp-90 also participates maintaining the signalling
function of the p56-lck kinase [14]. Since ZAP-70 is one
of the main substrates of p56-lck [15], and the ligand-free
GR is complexed by Hsp-90, we assume that these mole-
cules are in the same macromolecular compartment in
the cytoplasm. A recent study described that the glucocor-
ticoid hormone modulates the activity of lck and fyn
kinases in peripheral blood Th cells [16].
In a previous work, we have shown that Dexamethasone
(DX), a GR agonist causes rapid p56-lck dependent tyro-
sine phosphorylation of ZAP-70 in Jurkat cells, which
could be inhibited by GR antagonist pre-treatment [17].
Here, we report that in the presence of its agonist, the
GR co-precipitates with ZAP-70 in Jurkat cells and in
HeLa cells transfected with ZAP-70. We conﬁrmed this
GC-induced molecular association with confocal microsco-
py. The co-localization of the GR, ZAP-70, and Hsp-90
may explain our previous ﬁndings [17] suggesting possible
functional cross-link between the signaling pathways of
TcR–CD3 complex and glucocorticoid hormone, which
may participate in the ﬁne tuning of T-cell response, thymic
selection, and apoptosis processes.
Materials and methods
Cell lines. Jurkat cells, P116 (ZAP-70 deﬁcient Jurkat subclone), and
HeLa cells were cultured at 37 C in humidiﬁed atmosphere, containing
5% CO2, in RPMI medium supplemented with 5% (Jurkat cells) and 10%
(HeLa and P116 cells) fetal calf serum (Gibco).
Lentivirus production and transduction. Human full-length wild-type
ZAP-70 cDNA has been inserted in the pWPTS lentiviral transfer plasmid
under the control of an EF1 promoter as published elsewhere [18]. Len-
tivirus production and transduction of P116 and HeLa cell lines were
performed as described elsewhere [19,20].
Chemicals and buﬀers. All ﬁne chemicals were purchased from Sigma–
Aldrich, otherwise indicated. Dexamethasone (DX) and Geldanamycin
(GA) were dissolved in DMSO at a concentration of 4 and 1 mg/ml,
respectively. For intracellular free calcium measurement Fluo-3 AM
(Molecular Probes), 1 mg/ml stock solution was dissolved in Pluronic-F-
127 + DMSO. For the Western blot experiments, cells were lysed in an ice-
cold TEM buﬀer containing 50 mM NaCl, 10 mM Tris–HCl, pH 7.6,
4 mM EDTA, 20 mM sodium molybdate, and 10% glycerol). Aprotinin,
leupeptin (10 lg/ml), and PMSF (2 mM) were freshly added to the buﬀer.
For washing Western blots washing buﬀer (10 mM Tris, pH 7.4, 100 mM
NaCl, and 0.1% Tween-20) was used. The intracellular labelling for con-
focal microscopy was performed in saponine buﬀer (0.1% saponine, 0.1%
BSA, and 0.1% azide in PBS).
Antibodies. Immunoprecipitation was performed either with polyclonal
anti-ZAP-70 antibody generated by immunizing rabbits with a peptide
corresponding to the amino acids 485–499 of ZAP-70 sequence, or mousemonoclonal anti-GR antibody (clone 8E9) produced in our laboratory
[21]. For Western blotting, mouse monoclonal anti-ZAP-70 (clone: 29,
Transduction Laboratories) mouse monoclonal anti-GR antibody (clone
5E4, [21]), and rabbit polyclonal anti-HSP-90 (Santa Cruz Biotechnology)
were used. HRPO-conjugated goat anti-mouse IgG (Hunnavix) and anti-
rabbit IgG (Pierce) were applied as secondary antibodies. For confocal
microscopy, anti-GR-FITC (5E4), and phycoerythrin-conjugated mouse
monoclonal anti-ZAP-70 antibodies (eBioscience, 1E7.2) were used. FITC
and PE-conjugated mouse IgG1 isotype control antibodies (DakoCyto-
mation) were applied as negative controls.
Geldanamycin and Dexamethasone treatment of cells. Cells were incu-
bated overnight in complete RPMI medium in the presence of 1.78 lM
Geldanamycin or solvent (DMSO). After the incubation, cells were
washed in serum-free RPMI and subjected to DX treatment as described
previously [17]. Brieﬂy, cells were resuspended in RPMI at a concentration
of 108/ml and incubated at 37 C with 10 lM DX or solvent for 5 min.
After incubation, the reaction was stopped by placing the tubes in liquid
nitrogen (for Western blots) or with ice-cold PBS-azide (for microscopy).
Lysis, immunoprecipitation and Western blot. Ten million cells were
lysed in 500 ll TEM buﬀer by sonication on ice. Postnuclear supernatants
were aspirated and subjected to immunoprecipitation. Equal amounts of
cell lysates were incubated on a rotator platform at 4 C with 30 ll slurry
of protein G coupled Sepharose beads (Amersham) for 30 min. After the
removal of the pre-clearing beads, 10 ll antibody was added for 2 h. Then
protein G–Sepharose beads were added for additional 2 h. Beads were
washed ﬁve times with ice-cold washing buﬀer. The electrophoresis and
Western blotting of the samples were performed as described previously
[17].
Confocal microscopy. Cells were ﬁxed in 4% paraformaldehyde and
washed in saponine buﬀer. The labelling of the cells was performed in
saponine buﬀer with an antibody concentration of 1 lg/ml. After 1 h
incubation on ice, the cells were washed twice in saponine buﬀer and
layered onto slides. The excess ﬂuid was carefully aspirated and the slides
were covered using 50% glycerol–PBS. In case of HeLa–trZAP-70 cells,
the above process was performed on cell monolayers. The examination of
the samples was carried out using an Olympus Fluoview 300 confocal
microscope or later a Olympus Fluoview FV1000S-IX81 system.
Ca-signal measurement. Intracellular free calcium was measured
according to the protocol previously described by Boldizsar et al. [22].Results
The GR and Hsp-90 co-precipitates with ZAP-70 in the
lysates of DX treated Jurkat cells
As our previous results [17] indicated, GC induced rapid
phosphorylation of ZAP-70, therefore we investigated the
possible association of ZAP-70 and GR in Jurkat cells.
Immunoprecipitation was performed on lysates of DX or
vehicle-treated Jurkat cells, reciprocally with anti-ZAP-70
and anti-GR antibodies. Upon DX treatment, the co-pre-
cipitation of the two molecules increased, indicating that
agonist promoted the GR association with ZAP-70.
(Fig. 1A) To further characterise the subcellular localisa-
tion and relation of ZAP-70 and GR in the cytoplasm,
we visualised the two molecules simultaneously by confocal
microscopy. In vehicle-treated, resting Jurkat cells both
ZAP-70 and GR showed even, mostly cytoplasmic distri-
bution, (Fig. 1C) with almost no co-localisation. Upon
5 min high dose DX treatment, we observed co-localisation
of the two molecules clustered underneath the cell mem-
brane. (Fig. 1D) Investigating Hsp-90 relation to ZAP-70
by immunoprecipitation we found, that Hsp-90 co-precip-
Fig. 1. Association of ligand-bound GR with ZAP-70 in Jurkat cells. (A) Anti-GR and anti-ZAP-70 Western blots are shown from anti-GR or anti-ZAP-
70 precipitated Jurkat cell lysates with or without DX treatment. Equal amount of GR and ZAP-70 precipitated when anti-GR and anti-ZAP-70
antibodies were used for precipitation, respectively, while GR and ZAP-70 co-precipitation markedly increased in the DX-treated samples. (B) Anti-Hsp-
90 and anti-ZAP-70 Western blots are shown from anti-ZAP-70 precipitated Jurkat cell lysates with or without DX pretreatment. Anti-ZAP-70 was used
as precipitating antibody in all samples. Equal amount of Hsp-90 co-precipitated both in the control and DX treated samples. The amount of precipitated
ZAP-70 was found to be equal in all samples. The Western blots shown on the ﬁgure are representatives from three separate experiments. (C,D) Jurkat cell
samples were prepared after ﬁxation and intracellular a-GR-FITC (green channel) and a-ZAP-70-PE (red channel) labelling, followed by sedimentation
onto slides and examination with a confocal microscope. In the DX-treated samples, the GR and the ZAP-70 showed near-membrane co-localisation (DX,
D), while this phenomenon was absent in the untreated controls (Ctrl, C). The ﬁgure shows representative images from three separate experiments. (For
interpretation of the references in colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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not alter the association of the two molecules (Fig. 1B).The GR associates with ZAP-70 expressed in transgenic
HeLa cells
ZAP-70 is a T-and NK-cell speciﬁc molecule and it is also
in close relation with other lymphocyte speciﬁc molecules
e.g. p56-lck. We aimed to investigate whether the co-precip-
itation of the GR and ZAP-70 molecules were dependent on
these lymphocyte speciﬁc factors.We used a lentiviral vector
construct for transfecting ZAP-70 deﬁcient Jurkat cells (P-
116) and HeLa human epithelial carcinoma cells to stably
express the full-length ZAP-70. The ZAP-70 expression level
in transfected P116 cells was higher (MFI:98) than in Jurkat
cells (MFI:28) as tested by ﬂow cytometry. (Fig. 2A) More-
over, theZAP-70 constructwas fully functional in P-116 cells
as shown by anti-CD3 activation and calcium signal mea-
surement. (Fig. 2B) Despite the higher ZAP-70 expression
in ZAP-70 transfected P116 cells, the calcium signal was sim-
ilar to that of wild-type Jurkat cells (Fig. 2B).
TheZAP-70 expression level in transfectedHeLa cellswas
higher (MFI:108) than that of Jurkat cells (MFI:28) as tested
by ﬂow cytometry. (Fig. 3A) Reciprocal immunoprecipita-tions and immunoblotting with anti-ZAP-70 and anti-GR
antibodieswere performed fromHeLa–trZAP-70 cell lysates
(Fig. 3B). ZAP-70 co-precipitated withGR inHeLa–trZAP-
70 cells. The clustering required the presence of GR ligand
(Fig. 3B), similarly to what we have found in Jurkat cells
(Fig. 1A). Co-localisation of the twomolecules was also ver-
iﬁed with confocal microscopy. We observed intensive cyto-
plasmic staining of both the GR and ZAP-70 molecules in
both DX untreated and treated HeLa–trZAP-70 cells
(Fig. 3D and E, respectively). We found a perinuclear co-
localisation of ZAP-70 with GR in Hela–trZAP-70 cells
upon 5 min high dose DX treatment, (Fig. 3E) while in the
untreated samples both molecules showed even distribution
throughout the cytoplasm (Fig. 3D). Examining Hsp-90
relation to ZAP-70 by immunoprecipitation, we found that
Hsp-90 co-precipitated with ZAP-70 in HeLa–trZAP-70
cells, similarly to Jurkat cells. DX treatment did not alter
the association of the two molecules (Fig. 3B).ZAP-70 and Hsp-90 co-pecipitation in Jurkat lysates are
inhibited by GA
To better clarify the role of Hsp-90 in this signalling
process, we aimed to investigate whether GA, a speciﬁc
Fig. 2. Lentiviral transfection of P116 (ZAP-70 deﬁcient) cells with ZAP-70. (A) ZAP-70 expression of ZAP-70 transfected P116 cells was compared to
untransfected P116 and Jurkat cells by ﬂow cytometry after intercellular phycoerythrin (PE)-conjugated anti-ZAP-70 antibody labelling. Flow cytometric
histogram shows PE conjugated anti-ZAP-70 ﬂuorescence (FL2) of a representative measurement from three separate experiments. (B) Calcium signal of
ZAP-70 transfected P116 cells (m) was compared to untransfected P116 (d) and Jurkat cells (j). Diagrams show the result of a representative
measurement from three separate experiments.
Fig. 3. Liganded GR clustering with ZAP-70 in HeLa–trZAP-70 cells. (A) Representative ﬂow cytometric histograms show the ZAP-70 expression of
control and HeLa–trZAP-70 cells after labelling with phycoerythrin (PE)-conjugated anti-ZAP-70 antibody. (B) Anti-GR and anti-ZAP-70 blots are
shown from anti-GR or anti-ZAP-70 precipitated HeLa–trZAP-70 cell lysates with or without DX treatment. Equal amount of GR and ZAP-70
precipitated when anti-GR and anti-ZAP-70 antibodies were used for precipitation, respectively, while GR and ZAP-70 co-precipitated only in the DX-
treated samples. (C) Anti-Hsp-90 and anti-ZAP-70 blots are shown from anti-ZAP-70 precipitated HeLa–trZAP-70 cell lysates with or without DX
pretreatment. Anti-ZAP-70 was used as precipitating antibody in all samples. Equal amount of Hsp-90 co-precipitated both in the control and DX treated
samples. The amount of precipitated ZAP-70 was found to be equal in all samples. The Western blots shown in the ﬁgure are representatives from three
separate experiments. (D,E) Representative confocal microscopic pictures show HeLa–trZAP-70 cells grown in a monolayer after ﬁxation and intracellular
labelling with phycoerythrin conjugated anti-ZAP-70 antibody (red channel) and FITC-conjugated anti-GR antibody (green channel). Control cells are
depicted left (D) and Dexamethasone-treated cells are depicted right. (E) In the DX-treated samples the GR and the ZAP-70 showed perinuclear
co-localisation (E), while this phenomenon was absent in the untreated controls (D). The ﬁgure shows representative images from three separate
experiments. (For interpretation of the references in colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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association. We performed immunoprecipitation with
anti-ZAP-70 antibody. Although GA inhibited theco-precipitation of ZAP-70 with Hsp-90, it did not
impair the DX-induced GR–ZAP-70 association
(Fig. 4).
Fig. 4. Geldanamycin treatment does not inhibit the Dexamethasone-
induced ZAP-70–GR co-precipitation. Anti-GR, anti-Hsp-90, or anti-
ZAP-70 blots are shown from anti-ZAP-70 precipitated control or DX-
treated Jurkat cell lysates with or without Geldanamycin pretreatment.
Geldanamycin treatment did not inﬂuence the increased association of
ZAP-70 with GR upon DX treatment. Equal amount of Hsp-90 co-
precipitated with ZAP-70 both in the control and DX treated samples,
which was completely abrogated by Geldanamycin pre-treatment. The
amount of precipitated ZAP-70 was found to be equal in control and DX
treated samples with or without Geldanamycin pretreatment. The blots
shown are representatives from three separate experiments.
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Steroid hormones can exert rapid, non-genomic and
genomic hormone eﬀects [1]. Our recent ﬁnding was that
5 min, high dose GR agonist (Dexamethasone) treatment
causes rapid p56-lck-dependent tyrosine phosphorylation
of ZAP-70 in Jurkat cells [17]. In this study, we set out to
investigate the possible molecular link between the GR and
ZAP-70. We demonstrate here, that after short term, high
dose DX treatment GR co-precipitates with ZAP-70. We
also conﬁrmed the close relation of these twomolecules upon
DX treatment in the submembrane compartment of the
cytoplasm by confocal microscopy in Jurkat cells. Minimal
association was found between ZAP-70 and the GR in
DX untreated cells. This association oﬀers a plausible
explanation for the rapid GC-induced ZAP-70 tyrosine-
phosphorylation as described earlier [17]. GR associating
with ZAP-70 upon ligand binding, may modify latter’s con-
formation ormolecular environment,which in turnmay lead
to the tyrosine-phosporylation of ZAP-70.
ZAP-70 and p56-lck are lymphocyte speciﬁc molecules,
while the Hsp-90 and GR are ubiquitous. To clarify
whether the association of the GR and ZAP-70 was depen-
dent upon lymphocyte speciﬁc factors, we performed the
same investigations on HeLa–trZAP-70 cells. The ligand-
bound GR showed similar co-clustering with ZAP-70 in
the HeLa–trZAP-70 cells than in Jurkat cells. Interestingly,
we found diﬀerent co-localisation patterns in Jurkat and
HeLa–trZAP-70 cells. While the co-clustering of the two
molecules in Jurkat cells occurred in the submembrane
compartment, in HeLa–trZAP-70 cells perinuclear co-lo-
calisation was observed. Presumably in Jurkat cells, wherethe TcR-signalling machinery is complete, ZAP-70 is
directed towards the membrane during the signal transduc-
tion processes. In HeLa cells, where the transgenic
expressed ZAP-70 is somewhat incompatible, the partner
molecules sorting for membrane orientation are absent.
Based on this we conclude that the molecular association
between the liganded GR and the ZAP-70 is independent
of lymphocyte speciﬁc factors, but takes place in distinct
cellular compartments.
Hsp-90 is a molecular chaperone which associates with
several other proteins [2]. We found, that ZAP-70 is asso-
ciated with Hsp-90 in both Jurkat and transgenic HeLa
cells. Similarly to this, others have recently shown that
ZAP-70 is physically associated with Hsp-90 in B-CLL cells
[23]. Although ZAP-70 is a T- and NK-cell speciﬁc mole-
cule, it is pathologically expressed by malignant B-CLL
cells, where it is associated to the activated form of Hsp-
90 [23]. Castro and colleagues proposed that B-CLL cells,
similarly to many other tumor cells, express the ‘‘activated’’
form of Hsp-90, with high ATPase activity [23], existing in
multi-chaperone complexes [24], whereas normal cells
express Hsp-90 in its non-activated form, which does not
associate with ZAP-70 [23]. Our results here show that
the association of ZAP-70 with the Hsp-90 was indepen-
dent from the presence or absence of the GR agonist, but
it could be abrogated with the Hsp-90 antagonist GA. As
Jurkat cells are of malignant origin, the ZAP-70–Hsp-90
association might represent a new aspect of the leukemic
phenotype. It is accepted that the GR dissociates from
the Hsp-90 after ligand binding [3]. Here we describe the
ligand-dependent association of GR to ZAP-70, which can-
not be blocked by GA. Based on these data, we conclude
that Hsp-90 complexes a lot of client proteins in the cyto-
plasm, both ligand-free GR and ZAP-70 among others.
When GR ligand is present, the ZAP-70–GR association
increases and becomes Hsp-90 independent. We hypothes-
ise that ZAP-70 might exist in two forms in the cytoplasm
of Jurkat cells, depending on its association with Hsp-90. It
appears that there is a relatively constant amount of ZAP-
70 bound to Hsp-90, which is not aﬀected by GR agonist
treatment and therefore possibly is not involved in the
rapid GR-induced phosphorylation events. The non-Hsp-
90 bound ZAP-70 fraction, on the other hand, would asso-
ciate with the ligand-bound GR and, consequently, may be
involved in the cross talk between the TcR and GR signal-
ling pathways. If we take into consideration the ﬁndings of
Castro and colleagues [23], we can also speculate that the
fraction of ZAP-70 that associates to the ‘‘activated’’
Hsp-90 molecules present in the cytoplasm may represent
an inactive molecular fraction.
In conclusion, the results of our past [17] and present
work suggest the existence of a hitherto unknown function
of ZAP-70: it is posed at the junction between the GR and
TcR signal transduction pathways which may also be
aﬀected by the chaperone Hsp-90. However, the exact roles
of ZAP-70, p56-lck, GR, and Hsp-90 in the balance
between these events need further elucidation.
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